sofosbuvir has been researched along with ledipasvir in 316 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 248 (78.48) | 24.3611 |
| 2020's | 68 (21.52) | 2.80 |
| Authors | Studies |
|---|---|
| Dadej, A; Jelińska, A; Muszalska, I; Sobczak, A; Tomczak, S; Zając, M | 1 |
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Ding, X; Hyland, RH; Lawitz, E; McHutchison, JG; Membreno, FE; Mo, H; Pang, PS; Poordad, FF; Symonds, WT | 1 |
| Ding, X; Gane, EJ; Hyland, RH; McHutchison, JG; Pang, PS; Stedman, CA; Subramanian, GM; Svarovskaia, E; Symonds, WT | 1 |
| An, D; Bernstein, DE; Chojkier, M; Di Bisceglie, AM; Fried, MW; Ghalib, R; Gordon, SC; Herring, R; Hyland, RH; Kowdley, KV; Lawitz, E; McHutchison, JG; Muir, AJ; Pang, PS; Pockros, PJ; Pound, D; Reddy, KR; Rossaro, L; Rustgi, V; Ryan, M; Schiff, E; Shiffman, ML; Subramanian, GM; Svarovskaia, E; Symonds, WT | 1 |
| Hoofnagle, JH; Sherker, AH | 1 |
| Afdhal, N; Arora, S; Di Bisceglie, AM; Dvory-Sobol, H; Ghalib, R; Gitlin, N; Gordon, SC; Herring, R; Kwo, P; Lalezari, J; Lawitz, E; McHutchison, JG; Muir, AJ; Nahass, R; Nelson, DR; Pang, PS; Pockros, PJ; Reddy, KR; Schiff, E; Subramanian, GM; Sulkowski, M; Symonds, WT; Yang, JC; Younes, ZH; Zhu, Y | 1 |
| Afdhal, N; Agarwal, K; Bräu, N; Buggisch, P; Buti, M; Chojkier, M; Ding, X; Foster, GR; Gitlin, N; Jacobson, IM; Kwo, P; Mangia, A; Marcellin, P; McHutchison, JG; Mo, H; Muir, AJ; Pang, PS; Puoti, M; Romero-Gomez, M; Subramanian, GM; Symonds, WT; Yang, JC; Zarski, JP; Zeuzem, S | 1 |
| Feld, JJ | 1 |
| Sofia, MJ | 1 |
| German, P; Mathias, A; Moorehead, L; Pang, P; Vimal, M | 1 |
| Delaney, W; Dvory-Sobol, H; Lawitz, EJ; Mabery, E; McHutchison, J; Miller, MD; Mo, H; Skurnac, T; Svarovskaia, ES; Voitenleitner, C | 1 |
| Carroll, J | 1 |
| Fauci, AS; Kohli, A; Kottilil, S; Marti, MM; Masur, H; McHutchison, JG; Meissner, EG; Nelson, A; Osinusi, A; Pang, PS; Silk, R; Subramanian, GM; Townsend, K; Zhang, X | 1 |
| Firpi, RJ; Hilgenfeldt, E | 1 |
| Cornberg, M; Höner zu Siederdissen, C | 1 |
| Chan, J; Mohammad, RA; Smith, MA | 1 |
| Nelson, DR; Peter, J | 1 |
| Foster, GR | 1 |
| Abbott, S; Barrett, LL; Bon, D; Chavez, J; Diaz, G; Egerson, D; Fauci, AS; Gross, C; Herrmann, E; Jolley, TA; Kapoor, R; Kleiner, DE; Kohli, A; Kotb, C; Kottilil, S; Kwan, R; Marti, MM; Masur, H; McHutchison, J; Meissner, EG; Nelson, A; Osinusi, A; Pang, PS; Petersen, T; Polis, MA; Proschan, M; Sidharthan, S; Silk, R; Sims, Z; Sneller, M; Spurlin, E; Subramanian, GM; Symonds, WT; Talwani, R; Teferi, G; Townsend, K; Wood, BJ | 1 |
| Kumari, R; Nguyen, MH | 1 |
| Beckerman, R; Jiang, Y; Smith, NJ; Stepanova, M; Younossi, ZM | 1 |
| Floreani, A | 1 |
| Chhatwal, J; Dunn, MA; Kanwal, F; Roberts, MS | 1 |
| Afdhal, N; Henry, L; Hunt, SL; Kowdley, KV; Marcellin, P; Stepanova, M; Younossi, ZM; Zeuzem, S | 1 |
| Keating, GM | 1 |
| Borgia, SM; Rowaiye, A | 1 |
| Betular, J; Enomoto, H; Gao, B; Garrison, K; Genda, T; Ide, T; Ikeda, F; Ishizaki, A; Izumi, N; Knox, SJ; Korenaga, M; McHutchison, JG; Mizokami, M; Mo, H; Mochizuki, H; Nakane, K; Nirei, K; Nishigaki, Y; Omata, M; Omote, M; Pang, PS; Sakamoto, N; Symonds, WT; Takehara, T; Toda, N; Toyoda, H; Ueno, Y; Umemura, T; Yanase, M; Yatsuhashi, H; Yokosuka, O | 1 |
| Halász, T; Horváth, G; Hunyady, B; Makara, M | 1 |
| Bourlière, M; Bronowicki, JP; Carrieri, MP; Pol, S; Stepanova, M; Younossi, ZM | 1 |
| Kmietowicz, Z | 1 |
| Albert, ML; Casrouge, A; Decalf, J; Duffy, D; Kottilil, S; Masur, H; Meissner, EG | 1 |
| Gross, C; Kapoor, R; Kohli, A; Kotb, C; Kottilil, S; Lam, B; Masur, H; Nelson, A; Osinusi, A; Pang, PS; Polis, MA; Rustgi, V; Sidharthan, S; Silk, R; Sims, Z; Sugarman, K; Teferi, G | 1 |
| Baden, RP; Bräu, N; Colson, AE; Cooper, C; Dieterich, D; Dvory-Sobol, H; Gane, E; German, P; Jayaweera, D; Luetkemeyer, A; Marks, K; McHutchison, JG; Morales-Ramirez, JO; Naggie, S; Ni, L; Pang, PS; Ruane, P; Saag, M; Santana-Bagur, J; Sax, PE; Stamm, LM; Stedman, CA; Sulkowski, M; Tebas, P; Towner, WJ; Wong, DK; Workowski, K; Yang, JC | 1 |
| Brunetto, MR; De Luca, A; Messori, A; Zignego, AL | 1 |
| Hikita, H; Hiramatsu, N; Kai, Y; Morishita, N; Nakabori, T; Nawa, T; Oze, T; Saito, Y; Sakamori, R; Suemizu, H; Takehara, T; Tanaka, S; Tatsumi, T; Yakushijin, T | 1 |
| Escheik, C; Estep, M; Gerber, L; Stepanova, M; Weinstein, A; Younossi, ZM | 1 |
| An, D; Brainard, D; Gane, EJ; Hyland, RH; Pang, PS; Stedman, CA; Svarovskaia, E | 1 |
| Brainard, DM; Elsheikh, E; Gerber, L; McHutchinson, JG; Nader, F; Stamm, LM; Stepanova, M; Younossi, ZM | 1 |
| Bronowicki, JP; Hézode, C | 1 |
| Debes, JD; Ricci, P | 1 |
| Rino, Y; Yamamoto, N; Yukawa, N | 1 |
| Feld, JJ; Kottilil, S; O'Brien, TR; Pfeiffer, RM | 1 |
| Beckerman, R; Brown, A; Buti, M; Fagiuoli, S; Mauss, S; Rosenberg, W; Serfaty, L; Smith, N; Srivastava, A; Stepanova, M; Younossi, Z | 1 |
| Akoth, E; Chavez, J; Emmanuel, B; Gross, C; Kattakuzhy, S; Kohli, A; Kottilil, S; Lam, B; Masur, H; McLaughlin, M; McManus, M; Mo, H; Nelson, A; Osinusi, A; Polis, MA; Price, A; Shrivastava, S; Sidharthan, S; Silk, R; Sims, Z; Tang, L; Teferi, G; Wilson, E | 1 |
| Akoth, E; Gross, C; Kattakuzhy, S; Kohli, A; Kottilil, S; Masur, H; McHutchison, JG; McLaughlin, M; Mo, H; Nelson, A; Osinusi, A; Pang, PS; Price, A; Sidharthan, S; Silk, R; Sims, Z; Subramanian, GM; Tang, L; Wilson, EM | 1 |
| Bryce, CL; Chidi, AP; Fine, MJ; Good, CB; Myaskovsky, L; Rogal, S; Rustgi, VK; Smith, KJ; Tsung, A | 1 |
| Kohli, A; Kottilil, S; Masur, H; Meissner, EG; Osinusi, A; Remaley, AT; Sampson, M; Sidharthan, S; Tang, L; Townsend, K | 1 |
| Abbott, S; Akoth, E; Chavez, J; Emmanuel, B; Gross, C; Jolley, TA; Kattakuzhy, S; Kohli, A; Kottilil, S; Masur, H; McLaughlin, M; Meissner, EG; Mo, H; Nelson, A; Osinusi, A; Polis, MA; Price, A; Proschan, M; Seamon, C; Sidharthan, S; Silk, R; Sims, Z; Tang, L; Teferi, G; Wilson, E | 1 |
| Adhoute, X; Ansaldi, C; Benali, S; Bourlière, M; Castellani, P; Halfon, P; Oules, V; Portal, I | 1 |
| Chahal, HS; Fox, RK; Kahn, JG; Marseille, EA; Ollendorf, DA; Pearson, SD; Tice, JA | 1 |
| Butt, AA; Chung, RT; Shaikh, OS; Sherman, KE; Yan, P | 1 |
| Gish, R; Kohli, A; Manch, R; Nafisi, S; Roy, S | 1 |
| Chen, W; Chen, Y; Jin, L; Lin, W; Pan, C; Pan, Z; Zheng, Y; Zhou, G | 1 |
| Gordon, LA; Gross, C; Kohli, A; Kottilil, S; Masur, H; Nelson, A; Osinusi, A; Petersen, T; Polis, MA; Seamon, C; Tang, L; Townsend, K | 1 |
| Afdhal, NH; Eggleton, E; Knox, SJ; Kowdley, K; Mangia, A; Mizokami, M; Omata, M; Pang, P; Park, SH; Saab, S; Subramanian, M; Zhu, Y | 1 |
| Asselah, T; Boyer, N; Marcellin, P; Martinot-Peignoux, M; Saadoun, D | 1 |
| Kelley, C; McPhee, F; Signorovitch, J; Swallow, E; Wygant, G | 1 |
| Abergel, A; Asselah, T; Jiang, D; Kersey, K; Loustaud-Ratti, V; Metivier, S; Mo, H; Pang, PS; Samuel, D | 1 |
| Birati, EY; Forde, KA; Goldberg, LR; Padegimas, A | 1 |
| Alkhouri, N; Anthony, S; Guirguis, J; Hanouneh, IA; Rivas, J; Singh, T | 1 |
| Cheng, G; Corsa, A; Delaney, W; Doehle, B; Dvory-Sobol, H; Gong, R; Han, B; Lee, YJ; Link, JO; Mo, H; Pagratis, N; Peng, B; Perron, M; Tian, Y; Xu, S; Xu, Y; Yu, M | 1 |
| Henry, L; Nader, F; Stepanova, M; Younossi, ZM | 1 |
| Chang, TT; Chen, JJ; Chien, RN; Chu, CJ; Chuang, WL; Gao, B; Garrison, KL; Hsu, YC; Hu, TH; Kao, JH; Knox, SJ; Lo, GH; Mo, H; Pang, PS; Peng, CY; Sheen, IS; Wang, HY; Yang, JC | 1 |
| Kottilil, S; Polis, MA; Rosenthal, ES | 1 |
| Andreone, P; Gamal, N | 1 |
| Araújo, ES; Bourliere, M; Canini, L; Chiche, L; Coquet, E; Cotler, SJ; Dahari, H; Graw, F; Halfon, P; Penaranda, G; Renou, C; Riso, A; Uprichard, SL | 1 |
| Ferriols-Lisart, R; Guglieri-López, B; Merino-Sanjuán, M; Pérez-Pitarch, A | 1 |
| Chan, HLY; Choi, MS; Dan, YY; Henry, L; Lee, MH; Stepanova, M; Younossi, ZM; Yu, ML | 1 |
| Ciesek, S; Costa, R; Klempnauer, J; Lohse, AW; Lüthgehetmann, M; Manns, MP; Mix, H; Nashan, B; Otto, B; Pischke, S; Polywka, S; Proske, V; Sterneck, M; von Hahn, T; Wedemeyer, H | 1 |
| de Lagarde-Sebastián, M; de Miguel-Campo, B; Domínguez-Domínguez, L; Pulido, F | 1 |
| Henry, L; Hunt, S; Nader, F; Stepanova, M; Younossi, ZM | 1 |
| Holle, LM; Jensen, CM | 1 |
| Johnson, S; Marx, SE; Misurski, D; Parisé, H; Saab, S; Sanchez Gonzalez, Y; Virabhak, S; Wang, A | 1 |
| Nehra, V; Rizza, SA; Tan, EM; Temesgen, Z | 1 |
| Alshatti, F; Hull, MW; Moosavi, S; Yoshida, EM | 1 |
| Ferenci, P; Freissmuth, C; Graziadei, I; Gschwantler, M; Hametner, S; Hofer, H; Karpi, A; Kozbial, K; Laferl, H; Maieron, A; Moser, S; Ramona, AZ; Stauber, RE; Stern, R; Vogel, W; Zoller, HM | 1 |
| Al Zoairy, R; Beinhardt, S; Ferenci, P; Freissmuth, C; Hofer, H; Kozbial, K; Maieron, A; Schmidt, A; Stättermayer, AF; Stauber, R; Stern, R; Strasser, M; Trauner, M; Watschinger, B; Zoller, H | 1 |
| Tseng, A; Wong, DK | 1 |
| Cooper, C; Dieterich, D; Dvory-Sobol, H; Han, L; McHutchison, JG; Naggie, S; Pang, PS; Saag, M; Stamm, LM; Sulkowski, M; Yang, JC | 1 |
| Rosenthal, P; Smith, SK | 1 |
| Gschwantler, M; Haltmayer, H; Marchart, K; Moser, S; Schìtz, A | 1 |
| Chen, GF; Chen, J; Cheng, J; Dou, XG; Du, N; Duan, ZP; Fan, JG; Fu, QC; Han, Y; Hou, JL; Ji, D; Jia, JD; Jia, ZS; Lau, G; Li, B; Li, F; Liu, JL; Lu, LG; Niu, XX; Ren, H; Shang, J; Shao, Q; Wang, C; Wang, GQ; Wang, JP; Wang, XJ; Wang, YD; Wei, L; Wong, A; Wu, V; Xie, Q; Yang, XX; Zhang, WH; Zhang, YX; Zhuang, H | 1 |
| Henry, L; Hunt, S; Naggie, S; Stepanova, M; Sulkowski, M; Younossi, ZM | 1 |
| Backus, LI; Belperio, PS; Loomis, TP; Mole, LA; Shahoumian, TA | 1 |
| Basalious, EB; Bendas, ER; Karim, IA; Rezk, MR | 1 |
| Gonzalez, YS; Johnson, S; Juday, T; Misurski, D; Parisé, H; Saab, S; Virabhak, S; Wang, A | 1 |
| Brainard, DM; Dvory-Sobol, H; Gutierrez, JA; Hyland, RH; Lawitz, E; Liu, L; McHutchison, JG; Poordad, F; Wang, J | 1 |
| Abergel, A; Asselah, T; Jiang, D; Kersey, K; Knox, SJ; Loustaud-Ratti, V; Metivier, S; Pang, PS; Samuel, D; Svarovskaia, E | 1 |
| Akuta, N; Arase, Y; Fujiyama, S; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Saitoh, S; Sezaki, H; Suzuki, F; Suzuki, Y | 1 |
| An, D; Brainard, D; Gane, EJ; Hyland, RH; McHutchison, JG; Svarovskaia, ES | 2 |
| Aichelburg, MC; Bucsics, T; Chromy, D; Grabmeier-Pfistershammer, K; Mandorfer, M; Peck-Radosavljevic, M; Reiberger, T; Scheiner, B; Schwabl, P; Steiner, S; Trauner, M | 1 |
| Henry, L; Hunt, S; Nader, F; Stepanova, M; Younossi, Y; Younossi, ZM | 1 |
| Aghemo, A; Carrinola, R; Colombo, M; D'Ambrosio, R; Rossetti, V | 1 |
| Bannan, C; Bergin, C; Coghlan, M; De Gascun, CF; Dean, J; Farrell, G; Murray, C; Sevastianova, K | 1 |
| Bunnell, KL; Gallagher, MA; Glowacki, RC; Huhn, G; Osei, AM; Vibhakar, S | 1 |
| Aboelwafa, AA; Elkady, EF | 1 |
| Brainard, DM; Chuang, WL; Gane, E; Gao, B; Han, KH; Kao, JH; Sulkowski, MS; Yang, JC | 1 |
| Bienholz, A; Eisenberger, U; Gerken, G; Guberina, H; Herzer, K; Kribben, A; Willuweit, K; Witzke, O | 1 |
| Afdhal, NH; Bacon, BR; Curry, MP; Dieterich, DT; Flamm, SL; Guest, LE; Kowdley, KV; Lee, Y; Tapper, EB; Tsai, NC; Younossi, ZM | 1 |
| Baumgarten, A; Berger, F; Boesecke, C; Busch, H; Christensen, S; Hueppe, D; Ingiliz, P; Kimhofer, T; Lutz, T; Mauss, S; Rockstroh, JK; Schewe, K; Schmutz, G; Schulze zur Wiesch, J; Simon, KG; Wehmeyer, MH | 1 |
| Hunt, S; Mizokami, M; Omata, M; Stepanova, M; Walters, M; Younossi, ZM | 1 |
| Brainard, DM; Bronowicki, JP; Brown, A; Carr, V; Dore, GJ; Grebely, J; Kreter, B; Mauss, S; Natha, M; Puoti, M; Wyles, D; Yang, J; Yun, C; Zhu, Y | 1 |
| Abushouk, AI; Ahmed, H; Attia, A; Elgebaly, A; Hammad, AM; Negida, A | 1 |
| Chen, J; Fang, Z; Ou, P | 1 |
| Cure, S; Guerra, I; Igarashi, A; Lopresti, M; Marié, L; Tang, W | 1 |
| He, QF; Zhang, DZ; Zhang, QF | 1 |
| Cardoso, H; Gaspar, R; Macedo, G; Silva, M | 1 |
| Fortune, BE; Lim, JK; McCarty, TR; Njei, B | 1 |
| Bashir, A; Jarrad, A; Obed, A | 1 |
| Davis, MM; Johnson, SW; Priest, DH; Stever, LM | 1 |
| Beck, R; Berg, CP; Egetemeyr, DP; Lauer, UM; Malek, NP; Schwarz, JM; Werner, CR | 1 |
| da Silveira, E; Garcia, RT; Gish, RG; Huynh, A; Levitt, B; Ly, MT; Nguyen, HA; Nguyen, KK; Nguyen, MT; Trinh, HN; Wong, RJ; Yang, J | 1 |
| Henry, L; Younossi, Z | 1 |
| Beck, KR; Khalili, M; Kim, N | 1 |
| Assis Jarek, NA; Borba, HH; Ferreira, VL; Muzzillo, DA; Pontarolo, R; Tonin, FS; Wiens, A | 1 |
| Mazzucato, M | 1 |
| Bang, BR; Chopra, S; Cook, L; Elmasry, S; Feng, Z; Harper, T; Jerome, KR; Kahn, JA; Kanel, G; Kim, B; Saito, T; Wadhwa, S | 1 |
| Aghemo, A; Bourlière, M; Brainard, DM; Colombo, M; Dvory-Sobol, H; Hyland, R; Liu, H; Manns, M; Massetto, B; McHutchison, JG; Peck-Radosavljevic, M; Pol, S; Yun, C; Zhang, J | 1 |
| Elsheikh, E; Estep, JM; Gerber, L; Golabi, P; Karrar, A; Stepanova, M; Younossi, I; Younossi, ZM | 1 |
| Buti, M; Esteban, R; Llaneras, J; Riveiro-Barciela, M | 1 |
| Azuma, K; Dohmen, K; Furusyo, N; Hayashi, J; Higashi, N; Kajiwara, E; Kato, M; Kawano, A; Koyanagi, T; Nakamuta, M; Nomura, H; Ogawa, E; Satoh, T; Shimoda, S; Takahashi, K | 1 |
| Bassit, L; Benhamou, Y; Chen, G; Chen, J; Hou, J; Hsiao, HM; Ji, D; Jiang, Y; Ke, R; Lau, G; Li, B; Li, F; Li, J; Liu, J; Perelson, AS; Schinazi, RF; Shao, Q; Sun, J; Tao, S; Tsang, ST; Wang, C; Wang, Y; Wong, A; Wong, CL; Wu, V | 1 |
| Alonso, A; Franco, A; Gentil, MA; González-Corvillo, C; Hernández-Marrero, D; Jiménez-Martín, C; Lauzurica, LR; Perelló, M; Sánchez-Fructuoso, A; Zarraga, S | 1 |
| Eurich, D; Globke, B; Pratschke, J; Raschzok, N; Schott, E; Teegen, EM | 1 |
| Arterburn, S; Brainard, DM; Bzowej, NH; Dvory-Sobol, H; Hyland, RH; Levitsky, J; McHutchison, JG; Moonka, DK; O'Leary, JG; Terrault, NA; Verna, EC | 1 |
| Arizumi, T; Chishina, H; Hagiwara, S; Ida, H; Iwanishi, M; Komeda, Y; Kudo, M; Minami, T; Minami, Y; Nishida, N; Sakurai, T; Takita, M; Ueshima, K; Watanabe, T | 1 |
| Hashimoto, S; Hayashida, S; Honda, M; Inomata, Y; Isono, K; Oya, Y; Sasaki, Y; Sugawara, Y; Tanaka, M; Watanabe, T; Yamamoto, H; Yoshii, D; Yoshimaru, Y | 1 |
| Balistreri, WF; Bansal, S; Brainard, DM; German, P; Gonzalez-Peralta, RP; Jonas, MM; Kanwar, B; Kersey, K; Lin, CH; Massetto, B; Murray, KF; Rosenthal, P; Schwarz, K; Svarovskaia, E; Wen, J; Zhu, Y | 1 |
| Buggisch, P; Chaiyakunapruk, N; Curry, MP; Jeon, CY; Kowdley, KV; Latt, NL; Lee, Y; Lott, S; Petersen, J; Qureshi, K; Sahota, A; Sundaram, V; Tsai, N | 1 |
| Backstedt, D; Choi, M; Patel, A; Pedersen, MR; Seetharam, AB | 1 |
| Cornberg, M; Deterding, K; Gerken, G; Hardtke, S; Klinker, H; Koch, A; Manns, MP; Papkalla, A; Pathil, A; Schott, E; Schulze Zur Wiesch, J; Spengler, U; Spinner, CD; Umgelter, A; von der Leyen, H; von Witzendorff, D; Weber, K; Wedemeyer, H; Welzel, TM; Wiegand, J; Zeuzem, S; Zöllner, C | 1 |
| Chen, Y; Jiang, X; Song, Y; Tao, T | 1 |
| Guerra, I; Krauth, C; Liersch, S; Rossol, S; Stahmeyer, JT | 1 |
| Cameron, A; Fenkel, JM; Frank, AM; Shah, AP; Singh, P | 1 |
| Allerton, M; Lai, JB; Pauly, MP; Ready, J; Seo, S; Witt, DJ; Witt, MA | 1 |
| Altraif, IH | 1 |
| Balba, G; Bowlus, CL; Brainard, DM; Cohen, A; Fried, MW; Han, B; Hyland, RH; Kim, AY; Kouides, P; McHutchison, JG; Reddy, KR; Rhame, F; Sax, PE; Stamm, LM; Terrault, NA; von Drygalski, A; Walsh, CE; Wang, J; Workowski, K | 1 |
| Brainard, DM; Gane, EJ; Hyland, RH; McHutchison, JG; Stamm, LM; Stedman, CAM; Svarovskaia, E; Yang, Y | 1 |
| Akamatsu, N; Eguchi, S; Goto, R; Ikegami, T; Kitagawa, Y; Kokudo, N; Maehara, Y; Okajima, H; Shinoda, M; Soyama, A; Taketomi, A; Ueda, Y; Uemoto, S; Yoshizumi, T | 1 |
| Jansen, JW; Linneman, TW; Powderly, GM | 1 |
| Chen, N; Li, X; Pan, X; Ren, H; Weng, Q; Xie, J; Xu, J | 1 |
| Lim, SG | 1 |
| Aikata, H; Chayama, K; Imamura, M; Ishiyama, K; Kawakami, Y; Kawaoka, T; Morio, K; Nakamura, Y; Nelson Hayes, C; Ochi, H; Ohdan, H; Tsuge, M | 1 |
| Menéndez Naranjo, L; Vicente-Sánchez, S | 1 |
| Ammassari, A; Antinori, A; Fabbri, G; Grisetti, S; Mastrorosa, I; Mazzotta, V; Pinnetti, C; Vergori, A; Zaccarelli, M | 1 |
| Bourlière, M; Brainard, DM; Hyland, RH; Jiang, D; Marcellin, P; Pol, S; Vermehren, J; Welzel, TM; Zeuzem, S | 1 |
| Chen, J; Ou, P | 1 |
| Furuya, K; Iio, E; Ito, J; Izumi, T; Katagiri, M; Kawagishi, N; Kimura, M; Konno, J; Kumagai, K; Morikawa, K; Nakai, M; Natsuizaka, M; Ogawa, K; Ohara, M; Sakamoto, N; Shimada, N; Sho, T; Suda, G; Tanaka, Y; Tsubota, A; Umemura, M; Yamamoto, Y | 1 |
| Abo-Talib, NF; El-Ghobashy, MR; Tammam, MH | 1 |
| Bhamidimarri, KR; Burke, G; Chen, L; Ciancio, G; Guerra, G; Kupin, W; Ladino, M; Martin, P; Mattiazzi, A; Pedraza, F; Roth, D | 1 |
| Akhil, MS; Arumugam, K; Ganesh Prasad, NK; Kirushnan, B; Martin, M; Ravichandran, R | 1 |
| Fernández-Cuenca, F; López-Hernández, I; Paniagua-García, M; Ríos-Villegas, MJ | 1 |
| Biliotti, E; Esvan, R; Franchi, C; Palazzo, D; Serani, M; Silvestri, AM; Sorrentino, F; Spaziante, M; Taliani, G; Volpicelli, L | 1 |
| Hirayama, A; Matsuoka, S; Moriyama, M; Nakamura, H; Nirei, K; Yamana, Y; Yoda, S | 1 |
| Cheng, N; Ford, R; Maheshwari, R; Mgbemena, O; Norvell, JP; Parekh, S; Patel, A; Pillai, AA; Spivey, JR; Vora, R; Wedd, JP; Young, N | 1 |
| Abraham, GM; Spooner, LM | 1 |
| Bonfanti, P; Celesia, BM; De Socio, GV; Di Biagio, A; Maggi, P; Martinelli, C; Nicolini, LA; Quirino, T; Ricci, E; Squillace, N; Taramasso, L | 1 |
| Arai, M; Chiba, T; Haga, Y; Imazeki, F; Kanda, T; Kato, N; Maruyama, H; Nakamoto, S; Nakamura, M; Ogasawara, S; Ooka, Y; Saito, T; Sasaki, R; Suzuki, E; Takahashi, K; Tawada, A; Wu, S; Yasui, S; Yokosuka, O | 1 |
| Brainard, DM; Gane, EJ; Sulkowski, MS; Yang, JC | 1 |
| Balkan, II; Mete, B; Ozaras, R; Tabak, F; Yemisen, M | 1 |
| Brainard, DM; Hyland, RH; Lanzkron, S; McHutchison, JG; Moon, J; Sulkowski, M; Zhang, F | 1 |
| Augustyniak, K; Badurek, A; Baka-Ćwierz, B; Berak, H; Białkowska, J; Flisiak, R; Garlicki, A; Gietka, A; Janczewska, E; Kozielewicz, D; Mazur, W; Mozer-Lisewska, I; Musialik, J; Nowak, K; Olszok, I; Piekarska, A; Pleśniak, R; Sikorska, K; Simon, K; Stolarz, W; Tomasiewicz, K; Wawrzynowicz-Syczewska, M; Zarębska-Michaluk, D; Łucejko, M | 1 |
| Furusyo, N; Hayashi, T; Murata, M; Ogawa, E; Toyoda, K; Ura, K | 1 |
| Antinori, S; Binda, F; Giacomelli, A; Milazzo, L; Sollima, S; Torre, A | 1 |
| Angarano, G; Bruno, G; Dell'Acqua, R; Fabrizio, C; Lo Caputo, S; Milano, E; Milella, M; Monno, L; Saracino, A; Scudeller, L | 1 |
| Afdhal, NH; Bacon, B; Curry, MP; Dieterich, D; Flamm, SL; Guest, L; Kowdley, KV; Lee, Y; Milligan, S; Tapper, EB; Tsai, N; Younossi, Z | 1 |
| Goda, Y; Hakamatsuka, T; Hosoe, J; Kamakura, H; Maruyama, T; Masada, S; Tokumoto, H; Tsujimoto, T; Uchiyama, N | 1 |
| Brainard, DM; Lohse, AW; Mogalian, E; Scheurich, C; Schulze Zur Wiesch, J; von Felden, J; Yamamura, J | 1 |
| Mansour, FR | 1 |
| Andriulli, A; Barone, M; Brancaccio, G; Conti, F; Di Leo, A; Francavilla, R; Gatti, P; Iannone, A; Ippolito, AM; Lauletta, G; Masetti, C; Messina, V; Milella, M; Morisco, F; Napoli, N; Pesce, F; Santantonio, T; Shahini, E; Smedile, A; Termite, AP; Tundo, P | 1 |
| Brainard, DM; Corsa, AC; Hedskog, C; Kitrinos, KM; Miller, MD; Mo, H; Worth, A | 1 |
| Abutidze, A; Chkhartishvili, N; Dolmazashvili, E; Karchava, M; Sharvadze, L; Tsertsvadze, T | 1 |
| Guedj, J; Kohli, A; Kottilil, S; Nguyen, THT; Perelson, AS; Uprichard, SL | 1 |
| Abou-Samra, AB; Butt, AA; Simon, TG; Yan, P | 1 |
| Abolmagd, E; Abouserie, AA; Attia, KA; El-Olemy, A; Salama, FM | 1 |
| Anvesh, G; Rajesh, G; Raju, N; Raju, SB; Sridhar, N; Surendra, M; Vijay Kiran, B | 1 |
| Chen, DS; Chen, PJ; Chen, YS; Hong, CM; Kao, JH; Liu, CH; Liu, CJ; Su, TH; Wang, SS; Yang, HC | 1 |
| Aoki, T; Gatanaga, H; Kikuchi, Y; Kinai, E; Mizokami, M; Mizushima, D; Oka, S; Sugiyama, M; Teruya, K; Tsukada, K; Uemura, H; Watanabe, K | 1 |
| Chan, HLY; Dan, YY; Kruger, E; Lee, MH; Lim, YS; Tan, SC; Younossi, ZM | 1 |
| Do, S; Henry, L; Nguyen, MH; Nguyen, P; Nguyen, T; Trinh, H | 1 |
| Brown, AN; Drusano, GL; Li, E; Liu, L; Neely, MN; Rodriquez, JL; Schuster, L; Wang, GP; Yamada, W; Zhao, L | 1 |
| Brancaccio, G; Cantone, M; Ceccherini-Silberstein, F; Fabeni, L; Frigeri, F; Gaeta, GB; Genderini, F; Perno, CF; Pinto, A; Rizzo, V; Sorbo, MC | 1 |
| Frey, A; Gerken, G; Herzer, K; Piras-Straub, K; Timm, J; Walker, A | 1 |
| Agudelo, EZ; Campos-Varela, I; Roberts, JP; Sarkar, M; Terrault, NA | 1 |
| Boeker, K; Buggisch, P; Günther, R; Mauss, S; Niederau, C; Pathil, A; Schott, E; Simon, KG; Teuber, G; Vermehren, J; Vornkahl, HP; Wedemeyer, H; Zeuzem, S; Zimmermann, T | 1 |
| Kalal, C; Mohanka, R; Patel, P; Shah, S; Shukla, A; Vora, M | 1 |
| Al-Zoairy, R; Beinhardt, S; Ferenci, P; Graziadei, I; Hofer, H; Kozbial, K; Maieron, A; Rasoul-Rockenschaub, S; Stättermayer, AF; Stauber, R; Strasser, M; Trauner, M; Zoller, H | 1 |
| Allegre, T; Alric, L; Amri, I; Aumaitre, H; Bailly, F; Bellissant, E; Billaud, E; Bourlière, M; Carrieri, MP; Chas, J; Chevaliez, S; Cotte, L; De Truchis, P; Dominguez, S; Dupon, M; Fougerou-Leurent, C; Garraffo, R; Girard, PM; Jeantils, V; Lacombe, K; Leroy, V; Marcellin, F; Metivier, S; Molina, JM; Morlat, P; Naqvi, A; Neau, D; Pabic, EL; Pageaux, GP; Pailhé, A; Perré, P; Piroth, L; Poizot-Martin, I; Pol, S; Raffi, F; Renault, A; Reynes, J; Rosenthal, E; Salmon-Ceron, D; Teicher, E; Tual, C; Valantin, MA; Yazdanpanah, Y; Zucman, D | 1 |
| Enomoto, M; Fujii, H; Hagihara, A; Hai, H; Kawada, N; Kozuka, R; Morikawa, H; Motoyama, H; Murakami, Y; Tamori, A; Uchida-Kobayashi, S | 1 |
| Dore, GJ; Grebely, J; Hajarizadeh, B; Martinello, M; Matthews, GV | 1 |
| Elhenawee, M; Hashem, H; Ibrahim, AE; Saleh, H | 1 |
| Akushevich, L; Ben-Ari, Z; Fried, MW; Gallant, J; Hassan, M; Kuo, A; Landis, CS; Liapakis, AM; Lim, JK; Lok, AS; Michael, L; Nelson, DR; Park, JS; Pockros, PJ; Shiffman, ML; Terrault, NA; Vainorius, M; Zeuzem, S | 1 |
| Gschwantler, M; Gutic, E; Haltmayer, H; Lang, T; Luhn, J; Moser, S; Schleicher, M; Schubert, R; Schütz, A; Schwanke, C | 1 |
| Khalili, M; Mirzabeygi, V; Sohrabi, MR; Torabi Ziaratgahi, N | 1 |
| Khattak, MA; Kothapalli, A | 1 |
| Badr, KA; Bendas, ER; Rezk, MR | 1 |
| Doi, A; Furuta, K; Hikita, H; Imai, Y; Kai, Y; Kodama, T; Mita, E; Ohkawa, K; Sakamori, R; Tahata, Y; Takehara, T; Tatsumi, T; Yakushijin, T; Yamada, R | 1 |
| Desai, K; Desai, N; Kabrawala, M; Mehta, R; Nandwani, S; Parekh, V; Shah, J | 1 |
| Borba, HHL; Ferreira, VL; Leonart, LP; Pontarolo, R; Tonin, FS | 1 |
| Akuskevich, L; Frazier, LM; Fried, MW; Kuo, A; Levitsky, J; Li, E; Lim, JK; Liu, L; Morelli, G; Nelson, DR; Peter, J; Ramani, A; Reeves, JD; Sherman, KE; Terrault, N; Wang, GP; Zhao, L | 1 |
| Goldstein, DB; Kleinstein, SE; Naggie, S; Shea, PR; Stamm, LM; Sulkowski, M | 1 |
| Chamberland, S; Champsi, JH; Gittleman, LC; Hurley, LB; Korn, DG; Lai, JB; Lam, JO; Marcus, JL; Pauly, MP; Quesenberry, CP; Ready, J; Saxena, V; Seo, SI; Silverberg, MJ; Witt, DJ | 1 |
| Akahane, T; Hasebe, C; Itakura, J; Izumi, N; Joko, K; Kimura, H; Kobashi, H; Kojima, Y; Kondou, M; Kurosaki, M; Kusakabe, A; Mitsuda, A; Mori, N; Nakata, R; Narita, R; Ogawa, C; Sohda, T; Takaki, S; Takezawa, J; Tamada, T; Tsuji, K; Uchida, Y; Yagisawa, H | 1 |
| Benson, AA; Lederman, N; Safadi, R; Wolf, D | 1 |
| Gupta, E; Kataria, A; Nayak, SL; Sarin, SK | 1 |
| Easley, KA; Kalapila, AG; Kyle, AW; Michal, JL; Miller, LS; Patel, M; Rab, S | 1 |
| Ojha, RP; Steyerberg, EW | 1 |
| Höner Zu Siederdissen, C; Maasoumy, B | 1 |
| Brainard, D; Hedskog, C; Imai, Y; Inao, M; Kouyama, JI; Mo, H; Mochida, S; Motoya, D; Naiki, K; Nakamura, S; Nakayama, N; Sugawara, K; Tomiya, T; Uchida, Y | 1 |
| Gawęda, B; Kośnik, A; Krawczyk, M; Milkiewicz, P; Raszeja-Wyszomirska, J; Rejowski, S; Remiszewski, P | 1 |
| Ahn, SH; Chan, HL; Chuang, WL; Han, KH; Henry, L; Kao, JH; Lai, CL; Lim, YS; Nguyen, KV; Stepanova, M; Wei, L; Younossi, ZM | 1 |
| Enomoto, N; Maekawa, S | 1 |
| Andersen, ES; Bukh, J; Christensen, PB; Fahnøe, U; Gerstoft, J; Kjær, MS; Laursen, AL; Mössner, B; Pedersen, MS; Røge, BT; Schønning, K; Sølund, C; Weis, N | 1 |
| Abdel-Razek, W; Waked, I | 1 |
| Hamano, T; Inoue, M; Someda, H; Tachibana, N; Tsuzaki, K | 1 |
| El-Shorbagy, HI; Elbrashy, AM; Elsebaei, F; Hammad, SF | 1 |
| Elhenawee, M; Saleh, H; Saraya, RE | 1 |
| Abdel-Ghafar, TS; Abdelkareem, M; Abdelsameea, E; Abozeid, M; Alsebaey, A; Elfayomy, M; Elhelbawy, M; Fekry, M; Othman, W; Rewisha, E; Rgab, A; Sabry, A; Shebl, N; Waked, I | 1 |
| Chakraborty, S; Garlapati, P; Gayam, V; Gill, A; Guss, D; Khalid, M; Mandal, AK; Mansour, M; Mohanty, S; Mukhtar, O; Sherigar, J; Shrestha, B; Tiongson, B | 1 |
| Gandhi, M; Jhaveri, A; Merchant, R; Nagral, A; Nagral, N; Parikh, NS; Sawant, S | 1 |
| De, A; Kumar, P; Kumari, S; Singh, A; Singh, V | 1 |
| Chu, TC; MacDonald, BR; Marcus, JL; Ojha, RP | 1 |
| Abid, S; Abraham, P; Abu Bakar, N; Ahmed, T; Arisar, FAQ; Bwa, AH; Chen, KP; Dan, YY; Dhore, P; Eapen, CE; Goh, KL; Hamid, S; Hj Md Said, RB; Ho, SH; Jafri, W; Kamat, M; Koshy, A; Lee, YM; Lim, SG; Madan, K; Mehta, R; Mohamed, R; Phyo, WW; Piratvisuth, T; Shah, SR; Shukla, A; Tan, SS; Tanwandee, T; Tee, HP; Tyagi, S; Wadhawan, M; Win, KM; Yang, WL; Yin, TP | 1 |
| Abedi-Andani, M; Alavian, SM; Anvar, A; Behnava, B; Karimi-Sari, H; Khosravi, A; Namvar, A | 1 |
| Aghemo, A; Craviotto, V; Lamonaca, L; Lleo, A | 1 |
| Agarwal, K; Bruce, M; Carey, I; Spaan, M | 1 |
| Biggs, BA; Kanhutu, K; Sasadeusz, J; Schulz, TR; Watkinson, S | 1 |
| Cong, X; Feng, B; Jiang, HJ; Jin, Q; Luo, BF; Ma, DL; Wang, XX; Wei, L | 1 |
| Angelidakis, G; Blechacz, B; Economides, MP; Granwehr, BP; Hosry, J; Jiang, Y; Kaseb, A; Kyvernitakis, A; Mahale, P; Miller, E; Naing, A; Raad, II; Samaniego, F; Torres, HA | 1 |
| Enomoto, M; Hai, H; Kawada, N; Kumada, H; Okada, M; Tamori, A; Uchida-Kobayashi, S | 1 |
| Issa, YM; Mohamed, SH; Salim, AI | 1 |
| Chen, X; Deng, H; Hu, C; Huang, H; Li, W; Li, Y; Liu, J; Peng, Y; Ren, Y; Wu, T; Yuan, G; Zhang, YY; Zhou, Y | 1 |
| Sonderup, MW; Spearman, CW | 1 |
| Dohi, T; Jain, A; Kadry, Z; Krok, KL; Miller, D; Riley, TR; Schreibman, I; Sharma, R | 1 |
| Baker, MM; Belal, TS; Hammad, SF | 1 |
| Barreca, GS; Casalinuovo, F; Costa, C; Giancotti, A; Greco, G; Liberto, MC; Marascio, N; Matera, G; Mazzitelli, M; Pavia, G; Pisani, V; Serapide, F; Torti, C; Trecarichi, EM | 1 |
| Alexander, K; Anderson, PL; Blum, J; Brooks, KM; Bushman, LR; Castillo-Mancilla, JR; Ellison, L; Huntley, R; Kerr, BJ; Kiser, JJ; MacBrayne, CE; MaWhinney, S | 1 |
| Buggisch, P; Klinker, H; Lonjon-Domanec, I; Mauss, S; Müller, T; Nalpas, C; Pathil-Warth, A; Sarrazin, C; Schlag, M; Simon, KG; Wegner, S; Zimmermann, T | 1 |
| Collado, A; Corma-Gómez, A; De Los Santos Gil, I; Granados, R; Macías, J; Merino Muñoz, D; Morano, LE; Palacios, R; Pineda, JA; Téllez, F; Vera-Méndez, FJ | 1 |
| Cong, X; Feng, B; Jiang, HJ; Jin, Q; Kong, XS; Luo, BF; Qin, H; Wang, XX; Wei, L; Zhang, HY | 1 |
| Asensi-Diez, R; Del Rio-Valencia, JC; Muñoz-Castillo, I; Tamayo-Bermejo, R | 1 |
| Bagchi, S; Kottilil, S; Nelson, A; Poonia, B; Romani, S; Stafford, K | 1 |
| Arora, S; Dhiman, RK; Duseja, A; Grover, GS; Premkumar, M; Rathi, S; Roy, A; Satsangi, S; Taneja, S | 1 |
| Chen, JJ; Cheng, PN; Chiu, HC; Chiu, YC; Lee, PL; Tung, HD | 1 |
| Boglione, L; D'Avolio, A; De Nicolò, A; Di Perri, G | 1 |
| Abdelaty, LN; Elnaggar, AA; Hussein, RRS; Said, AA | 1 |
| Abe-Chayama, H; Aikata, H; Chayama, K; Fujino, H; Hayes, CN; Imamura, M; Kawaoka, T; Miki, D; Murakami, E; Nakahara, T; Ono, A; Osawa, M; Saito, Y; Serikawa, M; Teraoka, Y; Tsuge, M; Uchida, T | 1 |
| El Atrache, LL; Labidi, A | 1 |
| Amarsanaa, J; Baatarkhuu, O; Enkhtuya, D; Enkhzaya, S; Hsu, SJ; Ivshinkhorol, D; Jargalsaikhan, B; Kao, JH; Khosbayar, T; Lin, YY; Naranzul, N; Tsai, CH; Tseng, TC; Wang, TS | 1 |
| Aimono, Y; Kamoshida, T; Kogo, M; Kohyama, N; Yamamoto, T | 2 |
| Attia, D; El-Khayat, H; El-Shabrawi, M; Fouad, Y; Kamal, EM; Sameh, Y; Yakoot, M | 1 |
| Fernández-Cuenca, F; López-Hernández, I; Palacios-Baena, ZR; Paniagua-García, M; Ríos-Villegas, MJ | 1 |
| Abdel-Lateef, MA; Ali, R; Derayea, SM; Omar, MA | 1 |
| Giannini, EG; Indolfi, G | 1 |
| Applin, S; Asmuth, DM; Cox, S; Das, M; Goldstein, D; Guyer, B; Haubrich, RH; Hinestrosa, F; Huhn, GD; Jain, MK; Jiang, S; Nguyen-Cleary, T; Piontkowsky, D; Ramgopal, M; Rossaro, L; Ryu, JH; Slim, J | 1 |
| Dholaria, B; Juskevicius, R; Moreno Vanegas, YA | 1 |
| Heinz, A; Johnson, NL; Lasser, KE; Lee, KS; Quintiliani, L; Truong, V; Xuan, Z | 1 |
| Abdelmalek, MO; Abu-Faddan, NH; Ibrahim, ME; Kheila, AE; Mahmoud, AA; Makhlouf, NA | 1 |
| Ding, Y; Kersey, K; Li, C; Li, X; Shen, G; Zhang, H; Zhu, X | 1 |
| Feng, Z; Gao, H; Huang, R; Li, Z; Liang, X; Lin, T; Liu, S; Ma, J; Wang, X; Xu, L; Zhang, L | 1 |
| Chang, TS; Chen, CH; Chen, MY; Chen, WM; Chiu, WN; Hu, JH; Hu, TH; Hung, CH; Lu, CK; Lu, SN; Tung, SY; Wei, KL | 1 |
| Khalil, H; Kim, NG; Kullar, R; Saab, S | 1 |
| Chu, JN; Collins, J; Eweje, F; Faiz, MT; Gwynne, D; Hayward, A; Hess, K; Hua, T; Ishida, K; Katz, S; Koeppen, R; Langer, R; Lopes, A; McManus, R; Miller, JB; Salama, JAF; Slocum, AH; Soares, V; Steiger, C; Sulkowski, MS; Tamang, SM; Thomas, DL; Traverso, G; Verma, M | 1 |
| Bares, SH; Havens, JP; Regan, NN | 1 |
| Bruchfeld, A | 1 |
| Bertrand, D; Bouvier, N; Büchler, M; Caillard, S; Chevallier, E; Colosio, C; Garrouste, C; Gatault, P; Le Meur, Y; Rerolle, JP; Rivalan, J; Rostaing, L; Sayegh, J; Thierry, A | 1 |
| Chander, PN; Chugh, S; Singh, J; Solanki, S; Wolf, DC | 1 |
| Anderson, PL; Blum, J; Brooks, KM; Bushman, LR; Castillo-Mancilla, JR; Cendali, F; Choi, YJ; Gomez, J; Haas, H; Ibrahim, ME; Johnson, B; Kiser, JJ; MaWhinney, S; Morrow, M; Roon, L; Rowan, SE; Wyles, DL; Zheng, JH | 1 |
| Antonucci, R; Bartolini, E; Calvo, PL; Cananzi, M; Cangelosi, AM; D'Antiga, L; Di Dato, F; Dodi, I; Forlanini, F; Gaio, P; Garazzino, S; Giacomet, V; Indolfi, G; Iorio, R; Lenge, M; Mastrangelo, G; Nebbia, G; Nicastro, E; Nuti, F; Pinon, M; Ricci, S; Riva, S; Serranti, D; Silvestro, E; Trapani, S; Vajro, P | 1 |
| Fujiyama, N; Hedskog, C; Littman, M; Liu, LJ; Mizokami, M; Ng, LJ; Sekiya, T; Yuan, J | 1 |
| Chang, TT; Cheng, PN; Chien, SC; Chiu, HC; Chiu, YC; Wu, CH; Wu, IC; Yang, EH | 1 |
| Bogen, DL; Bunge, KE; Chappell, CA; Gaggar, A; Hillier, SL; Kirby, BJ; Krans, EE; Macio, IS; Meyn, LA; Scarsi, KK; Suri, V | 1 |
| Andrade, DC; Eckardt, PA; Huffman, V; Niu, J; Sherman, E | 1 |
| Abo-Talib, NF; Almehizia, AA; Amr, AEE; Asiri, YA; Ezzeldin, E; Tammam, MH | 1 |
| Aluzaite, K; Fraser, M; Giles, H; Johnson, S; Schultz, M | 1 |
| Ahn, SH; Amarsanaa, J; Baatarkhuu, O; Badamsuren, D; Batbayar, P; Choijamts, N; Enkhtuya, D; Gantuul, C; Gegeebadrakh, B; Han, KH; Kim, DY; Lee, JS; Naranzul, N; Otgonbayar, R; Otgonbold, J; Saruul, BU; Tuvshinbayar, N; Ulzmaa, G | 1 |
| Kang, SH; Kim, MY | 1 |
| Bahrami, G; Hatami, R; Keshavarzi, S; Majnooni, MB; Miraghaee, SS; Mohammadi, B; Sajadimajd, S | 1 |
| Abd-Elsalam, S; Abdellatif, RS; Abo-Amer, YE; Elbedewy, TA; Elsebaey, MA; Fouad, A; Mostafa, SM; Youssef, M | 1 |
| Abdullatif, H; Alem, SA; El-Karaksy, H; El-Raziky, MS; Eldeen, HG; Mogahed, EA; Nagy, A; Yasin, NA | 1 |
| Doi, A; Hikita, H; Kodama, T; Sakamori, R; Shigekawa, M; Shinkai, K; Tahata, Y; Takehara, T; Tatsumi, T; Yamada, R; Yamada, T | 1 |
| Adeboyejo, K; Agarwal, K; Aranday-Cortes, E; Ball, JK; Cramp, ME; da Silva Filipe, A; Davis, C; Irving, WL; McClure, CP; McLauchlan, J; Mutimer, D; Sreenu, V; Stone, B; Thomson, EC; Tong, L | 1 |
| Ehl, S; Maccari, ME; Speckmann, C; Thalhammer, J; Wegehaupt, O | 1 |
| Rabenjanahary, TH; Rakotozafindrabe, ALR; Ramanampamonjy, RM; Randriamifidy, NH; Rasolonjatovo, AS; Razafimahefa, SH; Razafindrazoto, CI | 1 |
| Aldunate, F; Chiodi, D; Cristina, J; Echeverría, N; Hernández, N; López, P; Moratorio, G; Moreno, P; Sánchez-Cicerón, A; Soñora, M | 1 |
| Akhan, S; Aktuğ Demir, N; Arslan Özel, S; Asan, A; Aygen, B; Barut, Ş; Batırel, A; Bilgin, H; Çağatay, A; Çelen, MK; Çelik, İ; Çetinkaya, RA; Demirtürk, N; Doğan, N; Ersöz, G; Gürbüz, Y; Hakyemez, İN; İnan, D; Kamalak Güzel, D; Karakeçili, F; Kınıklı, S; Konya, P; Korkmaz, P; Kuruüzüm, Z; Mıstık, R; Örmen, B; Öztürk, S; Saltoğlu, N; Şener, A; Şimşek, F; Şimşek, S; Suer, K; Tarakçı, H; Tülek, N; Tuna, N; Tuncer Ertem, G; Türker, N; Türkoğlu, E; Ural, O; Yıldız, O; Yıldız, U | 1 |
| Abbassi, MM; Ebeid, FS; El-Baraky, IA; El-Sayed, MH; Hassany, M; Sabry, NA | 1 |
| Biancone, L; Buggisch, P; Camargo, M; Chuang, WL; Dvory-Sobol, H; Gaggar, A; Hu, TH; Hyland, R; Kirby, BJ; Liu, CH; Lu, S; Mangia, A; Moreno, C; Osinusi, A; Peng, CY; Sise, ME; Su, WW | 1 |
| Arteaga, L; Brinkley, S; Brooner, RK; Falade-Nwulia, O; Haselhuhn, T; Herne, K; Katz, S; Latkin, C; Mehta, SH; Moon, J; Sulkowski, MS; Sutcliffe, CG; Ward, KM | 1 |
| Abbass, A; Abdeen, N; Afify, S; Alboraie, M; El Kassas, M; ELshazly, HM; Eltabbakh, M; Emadeldeen, M; Ezzat, S; Farghaly, R; Ghalwash, A; Hamdy, H; Omar, H; Omran, D; Salaheldin, M; Sweedy, A; Tahoon, M | 1 |
| Belal, F; El-Shorbagy, HI | 1 |
| Camus, G; Chang, TT; Chen, CY; Chen, JJ; Chen, PJ; Chien, RN; Chu, CJ; Chuang, WL; Gaggar, A; Hsu, YC; Hu, TH; Jiang, D; Liu, CJ; Lo, GH; Massetto, B; Peng, CY; Sheen, IS; Suri, V; Tseng, KC; Wang, HY; Yang, J; Zhang, F | 1 |
| Bair, MJ; Chang, CC; Chang, TS; Chen, CH; Chen, CT; Chen, CY; Chen, GY; Cheng, PN; Chong, LW; Chuang, WL; Dai, CY; Hsieh, TY; Hsiung, CK; Hu, JT; Huang, CF; Huang, CS; Huang, JF; Huang, YH; Hung, CH; Kao, CN; Kao, JH; Kuo, HT; Lee, MH; Lee, PL; Lee, TH; Lin, CL; Lin, CW; Lin, CY; Lin, HC; Liu, CH; Liu, CJ; Lo, CC; Mo, LR; Peng, CY; Su, WW; Tai, CM; Tsai, PC; Tsai, WL; Tseng, KC; Wang, CC; Wang, SJ; Wu, WC; Yang, CC; Yang, SS; Yeh, ML; Yu, ML | 1 |
| AlBayati, SM; Faraj, OA | 1 |
| Ebeid, FSE; El-Haddad, A; El-Sayed, MH; Elsayed, W; Gaggar, A; Kersey, K; Massetto, B; Zekri, AR; Zhang, F | 1 |
| Dobrzeniecka, A; Marczyńska, M; Pokorska-Śpiewak, M | 1 |
| Coşar, AM; Durak, S | 1 |
| Abd-Aal, MS; Abdel-Hafez, AS; Abdel-Hamid, TM; Abdel-Rahman, RZ; Abdelsalam, MFA; Elaatar, MB; Elgohary, MA; Elkady, AO; Elnagar, MT; Elnagdy, TR; Elsaied, MA; Emam, ME; Fatoh, AR; Hamada, MM; Hasan, EM; Helmy, S; Ibrahim, AA; Lotfy, HH; Mubark, MA; Nawar, OM; Sakr, MA; Seadawy, MG; Selem, MA; Shehata, MM; Zaki, AI | 1 |
| Bae, SH; Chang, UI; Choi, JY; Han, JW; Jang, JW; Kim, CW; Kim, HY; Kim, SH; Kwon, JH; Lee, HL; Lee, J; Lee, SK; Lee, SW; Nam, H; Nam, SW; Song, DS; Song, MJ; Sung, PS; Yang, H; Yang, JM; Yoo, SH; Yoon, SK | 1 |
| Dong, M; Evon, DM; Lok, AS; Michael, L; Nelson, DR; Peter, J; Reeve, BB; Stewart, PW | 1 |
| Abd Elghafar, MS; Abd-Elsalam, S; Abdelghaffar, H; Abdelghaffar, K; Al Shafie, A; Badr, M; El-Kassas, M; Esmael, HE; Ezz Eldin, AM; Ezzat, S; Hassany, SM; Kamal, DT; Karam-Allah, H; Medhat, MA; Moaz, I; Moustafa, E; Ossimi, A; Salama, M; Sayed, H; Shamseldeen, A | 1 |
| Abdine, HH; Aboras, SI; El-Yazbi, AF; Korany, MA; Ragab, MAA | 1 |
| Abdelaziz, A; Abdelgaied, MY; Abdelkawy, KS; Belal, F; El-Khodary, NM; Elmekawy, HA | 1 |
| AbouBakr, O; El Sayed Zaki, M; Ezz El Regal, M; Noaman, A; Sarhan, AA | 1 |
| Chua, JV; Ghosh, A; Kottilil, S; Nelson, AK; Price, AS | 1 |
| Fujita, K; Manabe, T; Masaki, T; Morishita, A; Nakahara, M; Ogawa, C; Ohura, K; Tadokoro, T; Tani, J | 1 |
| Hung, A; Seetasith, A; Wong, WB; Zullig, LL | 1 |
| Anderson, KE; Bonkovsky, HL; Faust, D; Hallberg, C; Hedstrom, K; Ma, CD; Moghe, A; Naik, H; Overbey, JR; Rudnick, SP; Wang, K | 1 |
| Ayadi, S; Ayari, M; Ghithia, N; Zaimi, Y | 1 |
| Charlton, C; Hlavay, BA; Klein, MB; Ogando, N; Power, C; Stapleton, JT; Zhuo, R | 1 |
35 review(s) available for sofosbuvir and ledipasvir
| Article | Year |
|---|---|
Hepatitis C - New drugs and treatment prospects.
Topics: Animals; Antiviral Agents; DNA-Directed RNA Polymerases; Enzyme Inhibitors; Hepatitis C; Humans; Molecular Structure; Molecular Targeted Therapy; Protease Inhibitors | 2019 |
Interferon-free strategies with a nucleoside/nucleotide analogue.
Topics: Animals; Antiviral Agents; Benzimidazoles; Drug Design; Drug Resistance, Viral; Fluorenes; Hepacivirus; Hepatitis C; Humans; Interferons; Molecular Targeted Therapy; Nucleosides; Nucleotides; Protease Inhibitors; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Nonstructural Proteins | 2014 |
Hepatitis C management in post-transplant patients.
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Fluorenes; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Oligopeptides; Polyethylene Glycols; Proline; Pyrrolidines; Recombinant Proteins; Recurrence; Ribavirin; Risk Factors; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uridine Monophosphate; Valine; Viral Load | 2015 |
[All-oral, interferon-free therapies for patients with chronic genotype 1 hepatitis C virus infection].
Topics: 2-Naphthylamine; Administration, Oral; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Approval; Drug Combinations; Fluorenes; Genotype; Germany; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Proline; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; Uracil; Uridine Monophosphate; Valine | 2014 |
Ledipasvir-sofosbuvir: interferon-/ribavirin-free regimen for chronic hepatitis C virus infection.
Topics: Adult; Animals; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Fluorenes; Genotype; Headache; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Nausea; Ribavirin; Sofosbuvir; Uridine Monophosphate | 2015 |
Optimal interferon-free therapy in treatment-experienced chronic hepatitis C patients.
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Precision Medicine; Pyrrolidines; Sofosbuvir; Uridine Monophosphate; Valine | 2015 |
Fixed-dose combination of sofosbuvir and ledipasvir for the treatment of chronic hepatitis C genotype 1.
Topics: Antiviral Agents; Benzimidazoles; Clinical Trials as Topic; Drug Combinations; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Liver Cirrhosis; Meta-Analysis as Topic; Recurrence; Sofosbuvir; Uridine Monophosphate; Viral Nonstructural Proteins | 2015 |
Ledipasvir/Sofosbuvir: a review of its use in chronic hepatitis C.
Topics: Antiviral Agents; Benzimidazoles; Fluorenes; Hepatitis C, Chronic; Humans; Sofosbuvir | 2015 |
[New era in the treatment of chronic hepatitis C - novel direct acting antivirals].
Topics: 2-Naphthylamine; Administration, Oral; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Clinical Trials as Topic; Cyclopropanes; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Interferons; Isoquinolines; Lactams, Macrocyclic; Liver Neoplasms; Macrocyclic Compounds; Nucleic Acid Synthesis Inhibitors; Proline; Protease Inhibitors; Pyrrolidines; Simeprevir; Sofosbuvir; Sulfonamides; Uracil; Uridine Monophosphate; Valine; Viral Load; Viral Nonstructural Proteins; Virus Replication | 2015 |
Ideal oral combinations to eradicate HCV: The role of ribavirin.
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Valine | 2016 |
Does herbal medicine reduce the risk of hepatocellular carcinoma?
Topics: Animals; Anti-Inflammatory Agents; Benzimidazoles; Carcinoma, Hepatocellular; Clinical Trials as Topic; Cysteine; Drug Combinations; Drugs, Chinese Herbal; Fatty Liver; Fluorenes; Glycine; Glycyrrhetinic Acid; Glycyrrhizic Acid; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Neoplasms; Non-alcoholic Fatty Liver Disease; Phytotherapy; Plant Preparations; Sofosbuvir; Tablets | 2015 |
Sofosbuvir plus ledipasvir in combination for the treatment of hepatitis C infection.
Topics: Antiviral Agents; Benzimidazoles; Drug Combinations; Drug Resistance, Viral; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Ribavirin; Sofosbuvir | 2015 |
Defining the possibilities: is short duration treatment of chronic hepatitis C genotype 1 with sofosbuvir-containing regimens likely to be as effective as current regimens?
Topics: Antiviral Agents; Benzimidazoles; Disease Management; Drug Administration Schedule; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Ribavirin; RNA, Viral; Sofosbuvir; Time Factors; Treatment Outcome; Viral Load | 2016 |
Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives.
Topics: 2-Naphthylamine; Amides; Anilides; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Protease Inhibitors; Quinoxalines; Sofosbuvir; Sulfonamides; Uracil; Valine; Viral Nonstructural Proteins | 2016 |
Sofosbuvir and ledipasvir for HIV/HCV co-infected patients.
Topics: Antiviral Agents; Benzimidazoles; Coinfection; Drug Interactions; Drug Resistance, Viral; Drug Therapy, Combination; Fluorenes; Hepatitis C, Chronic; HIV Infections; Humans; Sofosbuvir | 2016 |
Safety and efficacy of once daily ledipasvir/sofosbuvir fixed-dose combination in patients with chronic hepatitis C.
Topics: Antiviral Agents; Benzimidazoles; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Safety; Sofosbuvir | 2016 |
A model-based meta-analysis of sofosbuvir-based treatments in chronic hepatitis C patients.
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Models, Theoretical; Pyrrolidines; Simeprevir; Sofosbuvir; Valine | 2016 |
Ledipasvir-Sofosbuvir: A Once-Daily Oral Treatment Option for Chronic Hepatitis C Virus Genotype 1 Infection.
Topics: Administration, Oral; Benzimidazoles; Drug Combinations; Fluorenes; Genotype; Hepatitis C, Chronic; Humans; Sofosbuvir | 2016 |
Ledipasvir/sofosbuvir fixed-dose combination for treatment of hepatitis C virus genotype 4 infection.
Topics: Antiviral Agents; Benzimidazoles; Clinical Trials as Topic; Drug Combinations; Drug Interactions; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Sofosbuvir | 2016 |
Sexually-transmitted seronegative HCV infection in an HIV-positive post-liver transplant recipient. Case report and review of the literature.
Topics: Antiviral Agents; Benzimidazoles; Fluorenes; Hepatitis C; Hepatitis C Antibodies; HIV Infections; Humans; Liver Transplantation; Male; Middle Aged; RNA, Viral; Sexually Transmitted Diseases, Viral; Sofosbuvir; Transaminases; Transplant Recipients; Treatment Outcome | 2016 |
Sofosbuvir-based regimens for the treatment of hepatitis C virus in patients who underwent lung transplant: case series and review of the literature.
Topics: Adult; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Lung Transplantation; Middle Aged; Ribavirin; Sofosbuvir; Treatment Outcome | 2016 |
Safety and efficacy of sofosbuvir plus ledipasvir with and without ribavirin for chronic HCV genotype-1 infection: a systematic review and meta-analysis.
Topics: Animals; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Publication Bias; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir; Time Factors; Treatment Outcome; Viral Load | 2017 |
Efficacy and Safety of Ribavirin with Sofosbuvir Plus Ledipasvir in Patients with Genotype 1 Hepatitis C: A Meta-Analysis.
Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2016 |
Rapid Virological Response After Early Treatment with a Combined Therapy of Ledipasvir and Sofosbuvir in HCV Genotype 4 After Living Donor Liver Transplantation in a HCC Downstaged Patient: Case Report and Review of the Literature.
Topics: Antiviral Agents; Benzimidazoles; Carcinoma, Hepatocellular; Drug Therapy, Combination; Fluorenes; Hepatitis C, Chronic; Humans; Liver Neoplasms; Liver Transplantation; Living Donors; Male; Middle Aged; Sofosbuvir | 2016 |
Patient-reported and economic outcomes related to sofosbuvir and ledipasvir treatment for chronic hepatitis C.
Topics: Antiviral Agents; Benzimidazoles; Cost-Benefit Analysis; Fluorenes; Hepatitis C, Chronic; Humans; Medication Adherence; Sofosbuvir; Treatment Outcome; United States | 2016 |
Ledipasvir/sofosbuvir with or without ribavirin for the treatment of chronic hepatitis C genotype 1: A pairwise meta-analysis.
Topics: Antiviral Agents; Benzimidazoles; Databases, Bibliographic; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Randomized Controlled Trials as Topic; Ribavirin; Sofosbuvir; Treatment Outcome | 2017 |
Hepatitis C virus genotype 4: Genotype 1's little brother.
Topics: Antiviral Agents; Benzimidazoles; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Simeprevir; Sofosbuvir; Sustained Virologic Response | 2017 |
Eight weeks of ledipasvir/sofosbuvir is effective for selected patients with genotype 1 hepatitis C virus infection.
Topics: Adult; Benzimidazoles; Biopsy, Needle; Cohort Studies; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluorenes; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunohistochemistry; Male; Middle Aged; Patient Selection; Predictive Value of Tests; Recurrence; Risk Assessment; Severity of Illness Index; Sofosbuvir; Time Factors; Treatment Outcome | 2017 |
Efficacy and Safety of Ledipasvir/Sofosbuvir with and without Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: a meta-analysis.
Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome | 2017 |
Membranous nephropathy associated with hepatitis C virus infection treated with corticosteroids and Ledipasvir-Sofosbuvir: a case report and review of literature.
Topics: Aged; Anti-Inflammatory Agents; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Fluorenes; Glomerulonephritis, Membranous; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Prednisolone; Prognosis; Sofosbuvir | 2017 |
HCV management in resource-constrained countries.
Topics: Aminoisobutyric Acids; Antiviral Agents; Australia; Benzimidazoles; Carbamates; Continuity of Patient Care; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Drugs, Generic; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Risk Factors; Sofosbuvir; Sulfonamides; Valine | 2017 |
Reactivation of occult HBV infection in an HIV/HCV Co-infected patient successfully treated with sofosbuvir/ledipasvir: a case report and review of the literature.
Topics: Antiviral Agents; Benzimidazoles; Coinfection; Female; Fluorenes; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis C; HIV Infections; Humans; Middle Aged; Sofosbuvir | 2017 |
Sustained Virological Response in Special Populations with Chronic Hepatitis C Using Interferon-Free Treatments: A Systematic Review and Meta-analysis of Observational Cohort Studies.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cohort Studies; Cyclopropanes; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Simeprevir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uracil; Valine | 2018 |
2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C.
Topics: Benzimidazoles; Carbamates; Dose-Response Relationship, Drug; Drug Interactions; Fluorenes; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Kidney; Protease Inhibitors; Pyrrolidines; Sofosbuvir; Sulfonamides; Valine | 2018 |
Meeting the WHO hepatitis C virus elimination goal: Review of treatment in paediatrics.
Topics: Adolescent; Adult; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Child; Child, Preschool; Cyclopropanes; Disease Eradication; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Leucine; Pediatrics; Proline; Pyrrolidines; Quality of Life; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; World Health Organization | 2020 |
60 trial(s) available for sofosbuvir and ledipasvir
| Article | Year |
|---|---|
Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial.
Topics: Antiviral Agents; Benzimidazoles; Drug Administration Schedule; Drug Combinations; Female; Fluorenes; Genotype; Hepatitis C, Chronic; Humans; Male; Middle Aged; Protease Inhibitors; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome; Uridine Monophosphate; Viral Nonstructural Proteins | 2014 |
Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Enzyme Inhibitors; Fatigue; Female; Fluorenes; Furans; Genotype; Headache; Hepacivirus; Hepatitis C; Humans; Incidence; Male; Middle Aged; Nausea; Sofosbuvir; Thiophenes; Treatment Outcome; Uridine Monophosphate; Viral Nonstructural Proteins | 2014 |
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Uridine Monophosphate; Viral Load; Young Adult | 2014 |
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Combinations; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Nucleotidyltransferases; RNA-Dependent RNA Polymerase; Sofosbuvir; Uridine Monophosphate; Viral Load; Viral Nonstructural Proteins | 2014 |
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; RNA, Viral; Sofosbuvir; Uridine Monophosphate; Viral Load; Young Adult | 2014 |
Clinical and in vitro resistance to GS-9669, a thumb site II nonnucleoside inhibitor of the hepatitis C virus NS5B polymerase.
Topics: Adult; Antiviral Agents; Base Sequence; Benzimidazoles; Cell Line; Drug Resistance, Viral; Female; Fluorenes; Furans; Genetic Variation; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Microbial Sensitivity Tests; Molecular Sequence Data; Protein Binding; Quinolines; Ribavirin; Sequence Analysis, RNA; Sofosbuvir; Thiophenes; Treatment Outcome; Uridine Monophosphate; Viral Nonstructural Proteins | 2014 |
Re-treatment of chronic hepatitis C virus genotype 1 infection after relapse: an open-label pilot study.
Topics: Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Mutation; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir; Uridine Monophosphate | 2014 |
Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study.
Topics: Aged; Antiviral Agents; Benzimidazoles; Cohort Studies; Drug Therapy, Combination; Female; Fluorenes; Furans; Hepacivirus; Hepatitis C, Chronic; Humans; Intention to Treat Analysis; Male; Middle Aged; Quinolines; Ribavirin; RNA, Viral; Sofosbuvir; Thiophenes; Treatment Outcome; Uridine Monophosphate; Viral Load | 2015 |
Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antiviral Agents; Asian People; Benzimidazoles; Drug-Related Side Effects and Adverse Reactions; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Japan; Male; Middle Aged; Ribavirin; Sofosbuvir; Time Factors; Treatment Outcome; Uridine Monophosphate; Young Adult | 2015 |
The impact of ledipasvir/sofosbuvir on patient-reported outcomes in cirrhotic patients with chronic hepatitis C: the SIRIUS study.
Topics: Aged; Antiviral Agents; Benzimidazoles; Drug Monitoring; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Patient Outcome Assessment; Ribavirin; RNA, Viral; Sofosbuvir | 2016 |
Dynamic Changes of Post-Translationally Modified Forms of CXCL10 and Soluble DPP4 in HCV Subjects Receiving Interferon-Free Therapy.
Topics: Adult; Antiviral Agents; Benzimidazoles; Chemokine CXCL10; Convalescence; Dipeptidyl Peptidase 4; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Male; Protein Processing, Post-Translational; Recurrence; Ribavirin; Sofosbuvir; Treatment Outcome; Viral Load; Virus Replication | 2015 |
Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study.
Topics: Aged; Benzimidazoles; DNA, Viral; Drug Combinations; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Sofosbuvir; Viral Load | 2015 |
Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1.
Topics: Anti-Retroviral Agents; Antiviral Agents; Benzimidazoles; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Male; Middle Aged; RNA, Viral; Sofosbuvir; Uridine Monophosphate; Viral Load | 2015 |
Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection.
Topics: Adult; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; New Zealand; Random Allocation; Ribavirin; RNA, Viral; Sofosbuvir; Time Factors; Treatment Outcome; Viral Load | 2015 |
Ledipasvir/sofosbuvir treatment of hepatitis C virus is associated with reduction in serum apolipoprotein levels.
Topics: Antiviral Agents; Apolipoproteins; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; Sofosbuvir | 2015 |
Moderate Sustained Virologic Response Rates With 6-Week Combination Directly Acting Anti-Hepatitis C Virus Therapy in Patients With Advanced Liver Disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Cohort Studies; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Quinolines; Sofosbuvir; Treatment Outcome; Young Adult | 2016 |
Successful Retreatment of Chronic HCV Genotype-1 Infection With Ledipasvir and Sofosbuvir After Initial Short Course Therapy With Direct-Acting Antiviral Regimens.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; High-Throughput Nucleotide Sequencing; Humans; Male; Middle Aged; Retreatment; Sequence Analysis, DNA; Sofosbuvir; Treatment Outcome; Viral Load; Viral Nonstructural Proteins | 2016 |
Interferon-Free Treatment of Hepatitis C Virus in HIV/Hepatitis C Virus-Coinfected Subjects Results in Increased Serum Low-Density Lipoprotein Concentration.
Topics: Antiviral Agents; Benzimidazoles; Cardiovascular Diseases; Cholesterol, LDL; Coinfection; Drug Therapy, Combination; Dyslipidemias; Female; Fluorenes; Furans; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Male; Middle Aged; Prospective Studies; Quinolines; Ribavirin; Sofosbuvir; Thiophenes; Uridine Monophosphate | 2016 |
Four-Week Direct-Acting Antiviral Regimens in Noncirrhotic Patients With Hepatitis C Virus Genotype 1 Infection: An Open-Label, Nonrandomized Trial.
Topics: Antiviral Agents; Benzimidazoles; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Furans; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; Male; Middle Aged; Quinolines; RNA, Viral; Sofosbuvir; Thiophenes; Treatment Outcome; Viral Load | 2015 |
Effect of HIV co-infection on adherence to a 12-week regimen of hepatitis C virus therapy with ledipasvir and sofosbuvir.
Topics: Antiviral Agents; Benzimidazoles; Coinfection; Female; Fluorenes; Hepatitis C, Chronic; HIV Infections; Humans; Male; Medication Adherence; Middle Aged; Sofosbuvir; Urban Population | 2016 |
Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study.
Topics: Administration, Oral; Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; France; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; RNA, Viral; Sofosbuvir; Treatment Outcome; Viral Load | 2016 |
Patient-Reported Outcomes of Elderly Adults with Chronic Hepatitis C Treated with Interferon- and Ribavirin-Free Regimens.
Topics: Aged; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepatitis C, Chronic; Humans; Interferons; Male; Ribavirin; Sofosbuvir; Treatment Outcome | 2016 |
Ledipasvir/sofosbuvir fixed-dose combination tablet in Taiwanese patients with chronic genotype 1 hepatitis C virus.
Topics: Adult; Aged; Benzimidazoles; Carbamates; Drug Combinations; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Sofosbuvir; Tablets; Taiwan; Treatment Outcome | 2016 |
An In-Depth Analysis of Patient-Reported Outcomes in Patients With Chronic Hepatitis C Treated With Different Anti-Viral Regimens.
Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Interferons; Male; Middle Aged; Patient Reported Outcome Measures; Retrospective Studies; Ribavirin; Sofosbuvir | 2016 |
Sofosbuvir and ledipasvir improve patient-reported outcomes in patients co-infected with hepatitis C and human immunodeficiency virus.
Topics: Adult; Antiviral Agents; Benzimidazoles; Efficiency; Fatigue; Female; Fluorenes; Hepatitis C, Chronic; HIV Infections; Humans; Male; Middle Aged; Patient Satisfaction; Sofosbuvir; Treatment Outcome | 2016 |
Ledipasvir/sofosbuvir-based treatment of patients with chronic genotype-1 HCV infection and cirrhosis: results from two Phase II studies.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Sofosbuvir | 2016 |
No Evidence of Reactivation of Hepatitis B Virus Among Patients Treated With Ledipasvir-Sofosbuvir for Hepatitis C Virus Infection.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Coinfection; Drug Therapy, Combination; Female; Fluorenes; Hepatitis B; Hepatitis B virus; Hepatitis C; Humans; Male; Middle Aged; Sofosbuvir; Virus Activation | 2016 |
Sofosbuvir and Ledipasvir for 8 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Infection in HCV-Monoinfected and HIV-HCV-Coinfected Individuals: Results From the German Hepatitis C Cohort (GECCO-01).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Coinfection; Female; Fluorenes; Germany; Hepatitis C, Chronic; HIV Infections; Humans; Male; Middle Aged; Prospective Studies; Sofosbuvir; Viral Load; Young Adult | 2016 |
Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials.
Topics: Adult; Antiviral Agents; Benzimidazoles; Data Interpretation, Statistical; Drug Therapy, Combination; Drug Users; Enzyme-Linked Immunosorbent Assay; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Opiate Substitution Treatment; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Viral Load | 2016 |
Treatment With Ledipasvir-Sofosbuvir for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic Hepatitis C Virus Genotype 1 or 4 Infection: A Randomized Trial.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Genotype; Glomerular Filtration Rate; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Sofosbuvir | 2017 |
Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study.
Topics: Administration, Oral; Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluorenes; Follow-Up Studies; Hepatitis C, Chronic; Humans; Imidazoles; Intention to Treat Analysis; Isoquinolines; Male; Middle Aged; Proof of Concept Study; Pyrrolidines; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Valine; Viral Load | 2016 |
Perioperative Ledipasvir-Sofosbuvir for HCV in Liver-Transplant Recipients.
Topics: Antiviral Agents; Benzimidazoles; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Transplantation; Perioperative Care; RNA, Viral; Sofosbuvir | 2016 |
Ledipasvir and sofosbuvir for recurrent hepatitis C after liver transplantation.
Topics: Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepatitis C, Chronic; Humans; Liver Transplantation; Male; Middle Aged; Pilot Projects; Sofosbuvir; Treatment Outcome | 2017 |
The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infection.
Topics: Administration, Oral; Adolescent; Antiviral Agents; Benzimidazoles; Child; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Fluorenes; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Patient Safety; Risk Assessment; Severity of Illness Index; Sofosbuvir; Treatment Outcome; Viral Load | 2017 |
Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study.
Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Germany; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Prospective Studies; RNA, Viral; Sofosbuvir | 2017 |
Efficacy of Ledipasvir Plus Sofosbuvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2 Infection.
Topics: Antiviral Agents; Benzimidazoles; Drug Combinations; Fatigue; Female; Fluorenes; Genotype; Headache; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Nausea; Sofosbuvir; Sustained Virologic Response | 2017 |
Nonstructural protein 5A resistance profile in patients with chronic hepatitis C treated with ledipasvir-containing regimens without sofosbuvir.
Topics: Antiviral Agents; Benzimidazoles; Drug Resistance, Viral; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Sequence Analysis, DNA; Sofosbuvir; Sustained Virologic Response; Viral Nonstructural Proteins | 2018 |
The paradox of highly effective sofosbuvir-based combination therapy despite slow viral decline: can we still rely on viral kinetics?
Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Furans; Hepacivirus; Hepatitis C, Chronic; Humans; Kinetics; Male; Models, Theoretical; Quinolines; Sofosbuvir; Sustained Virologic Response; Thiophenes; Treatment Outcome; Uridine Monophosphate; Viral Load | 2017 |
Interferon-free therapy with direct acting antivirals for HCV/HIV-1 co-infected Japanese patients with inherited bleeding disorders.
Topics: Adult; Antiviral Agents; Benzimidazoles; Carbamates; Coinfection; Drug Therapy, Combination; Female; Fluorenes; Hemophilia A; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Imidazoles; Interferons; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; RNA, Viral; Sofosbuvir; Valine; Viral Load | 2017 |
Open Label Study of 8 vs. 12 Weeks of Ledipasvir/Sofosbuvir in Genotype 6 Treatment Naïve or Experienced Patients.
Topics: Aged; Antiviral Agents; Benzimidazoles; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Sofosbuvir; Sustained Virologic Response | 2017 |
Efficacy, safety and patient-reported outcomes of ledipasvir/sofosbuvir in NS3/4A protease inhibitor-experienced individuals with hepatitis C virus genotype 1 and HIV coinfection with and without cirrhosis (ANRS HC31 SOFTRIH study).
Topics: Aged; Benzimidazoles; Coinfection; Drug Administration Schedule; Female; Fibrosis; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Patient Reported Outcome Measures; Pilot Projects; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2018 |
The presence of multiple NS5A RASs is associated with the outcome of sofosbuvir and ledipasvir therapy in NS5A inhibitor-naïve patients with chronic HCV genotype 1b infection in a real-world cohort.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Resistance, Viral; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Mutation, Missense; Sequence Analysis, DNA; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Viral Nonstructural Proteins | 2018 |
Drug Interchangeability of Generic and Brand Products of Fixed Dose Combination Tablets of Sofosbuvir and Ledipasvir (400/90 mg): Employment of Reference Scaled Average Bioequivalence Study on Healthy Egyptian Volunteers.
Topics: Adolescent; Adult; Area Under Curve; Benzimidazoles; Chromatography, Liquid; Cross-Over Studies; Drug Compounding; Drug Therapy, Combination; Drugs, Generic; Egypt; Female; Fluorenes; Healthy Volunteers; Humans; Male; Middle Aged; Reference Standards; Sofosbuvir; Tablets; Tandem Mass Spectrometry; Therapeutic Equivalency; Young Adult | 2018 |
Association of CYP2B6 Single-Nucleotide Polymorphisms Altering Efavirenz Metabolism With Hepatitis C Virus (HCV) Treatment Relapse Among Human Immunodeficiency Virus/HCV-Coinfected African Americans Receiving Ledipasvir/Sofosbuvir in the ION-4 Trial.
Topics: Alkynes; Antiviral Agents; Benzimidazoles; Benzoxazines; Black or African American; Cohort Studies; Coinfection; Cyclopropanes; Cytochrome P-450 CYP2B6; Drug Therapy, Combination; Female; Fluorenes; Genome-Wide Association Study; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Male; Polymorphism, Single Nucleotide; Recurrence; Sofosbuvir | 2018 |
Sofosbuvir and ledipasvir are associated with high sustained virologic response and improvement of health-related quality of life in East Asian patients with hepatitis C virus infection.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; China; Female; Fluorenes; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Quality of Life; Republic of Korea; Ribavirin; Sofosbuvir; Surveys and Questionnaires; Sustained Virologic Response; Taiwan; Treatment Outcome | 2018 |
Outcome and adverse events in patients with chronic hepatitis C treated with direct-acting antivirals: a clinical randomized study.
Topics: 2-Naphthylamine; Adult; Anemia; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Therapy, Combination; Fatigue; Female; Fluorenes; Genotype; Headache; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uracil; Valine; Viral Load | 2018 |
Peripheral PD-1
Topics: Adult; Antiviral Agents; Benzimidazoles; CD8-Positive T-Lymphocytes; Cytokines; Drug Therapy, Combination; Female; Fluorenes; Furans; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Pilot Projects; Programmed Cell Death 1 Receptor; Quinolines; Receptors, Immunologic; Sofosbuvir; Sustained Virologic Response; T-Lymphocytes; Thiophenes; Viral Load | 2019 |
Decentralized care with generic direct-acting antivirals in the management of chronic hepatitis C in a public health care setting.
Topics: Adult; Antiviral Agents; Benzimidazoles; Clinical Protocols; Delivery of Health Care; Disease Eradication; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; India; Liver Cirrhosis; Male; Public Health; Ribavirin; Sofosbuvir; Sustained Virologic Response; Telemedicine | 2019 |
Effects of sofosbuvir/ledipasvir therapy on chronic hepatitis C virus genotype 4, infected children of 3-6 years of age.
Topics: Antiviral Agents; Benzimidazoles; Child; Child, Preschool; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Prospective Studies; Sofosbuvir; Treatment Outcome | 2020 |
HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens.
Topics: Adenine; Adult; Aged; Alanine; Benzimidazoles; Coinfection; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Female; Fluorenes; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Male; Middle Aged; RNA, Viral; Sofosbuvir; Tenofovir | 2020 |
Pharmacokinetics, Safety, and Tolerability of Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir in Healthy Chinese Subjects.
Topics: Adult; Antiviral Agents; Benzimidazoles; Carbamates; China; Female; Fluorenes; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Sofosbuvir | 2020 |
Efficacy of Sofosbuvir/Ledipasvir in Adolescents With Chronic Hepatitis C Genotypes 1, 3, and 4: A Real-world Study.
Topics: Adolescent; Antiviral Agents; Benzimidazoles; Child; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Prospective Studies; Sofosbuvir; Treatment Outcome | 2021 |
Ledipasvir plus sofosbuvir in pregnant women with hepatitis C virus infection: a phase 1 pharmacokinetic study.
Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Infant; Pregnancy; Pregnant Women; Sofosbuvir; Treatment Outcome | 2020 |
Nonadherence to Ledipasvir/Sofosbuvir Did Not Predict Sustained Virologic Response in a Randomized Controlled Trial of Human Immunodeficiency Virus/Hepatitis C Virus Coinfected Persons Who Use Drugs.
Topics: Antiviral Agents; Benzimidazoles; Coinfection; Fluorenes; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Pharmaceutical Preparations; Sofosbuvir; Substance-Related Disorders; Sustained Virologic Response; Treatment Outcome | 2022 |
Ledipasvir-sofosbuvir in Adolescents With Chronic Hepatitis C and Hematological Malignancies Undergoing Chemotherapy.
Topics: Adolescent; Antiviral Agents; Benzimidazoles; Child; Diarrhea; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hematologic Neoplasms; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Sofosbuvir; Treatment Outcome | 2022 |
Efficacy of Sofosbuvir plus Ledipasvir in Egyptian patients with COVID-19 compared to standard treatment: a randomized controlled trial.
Topics: Antiviral Agents; Benzimidazoles; COVID-19 Drug Treatment; Drug Therapy, Combination; Egypt; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; SARS-CoV-2; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2022 |
Sustainable and equivalent improvements in symptoms and functional well-being following viral cure from ledipasvir/sofosbuvir versus elbasvir/grazoprevir for chronic hepatitis C infection: Findings from the randomized PRIORITIZE trial.
Topics: Amides; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Fatigue; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Nausea; Quinoxalines; Sofosbuvir; Sulfonamides | 2022 |
Sofosbuvir/ledipasvir in combination or nitazoxanide alone are safe and efficient treatments for COVID-19 infection: A randomized controlled trial for repurposing antivirals.
Topics: Antiviral Agents; Benzimidazoles; COVID-19 Drug Treatment; Drug Repositioning; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Humans; Nitro Compounds; SARS-CoV-2; Sofosbuvir; Thiazoles; Treatment Outcome; Viral Load | 2022 |
Statins Increase the Bioavailability of Fixed-Dose Combination of Sofosbuvir/Ledipasvir by Inhibition of P-glycoprotein.
Topics: Antiviral Agents; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzimidazoles; Biological Availability; Cross-Over Studies; Drug Combinations; Fluorenes; Hepatitis C, Chronic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Sofosbuvir | 2022 |
A Phase 2 open label study of ledipasvir/sofosbuvir for 12 weeks in subjects with hepatitis B virus infection.
Topics: Antiviral Agents; DNA, Viral; Fluorenes; Hepacivirus; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Pilot Projects; Retrospective Studies; Sofosbuvir; Symptom Flare Up | 2023 |
221 other study(ies) available for sofosbuvir and ledipasvir
| Article | Year |
|---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Therapy for hepatitis C--the costs of success.
Topics: Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Sofosbuvir; Uridine Monophosphate | 2014 |
Beyond sofosbuvir: what opportunity exists for a better nucleoside/nucleotide to treat hepatitis C?
Topics: Antiviral Agents; Benzimidazoles; Drug Approval; Drug Discovery; Fluorenes; Hepatitis C, Chronic; Humans; Nucleosides; Nucleotides; Sofosbuvir; Uridine Monophosphate | 2014 |
Lack of a clinically important pharmacokinetic interaction between sofosbuvir or ledipasvir and hormonal oral contraceptives norgestimate/ethinyl estradiol in HCV-uninfected female subjects.
Topics: Adult; Antiviral Agents; Area Under Curve; Benzimidazoles; Contraceptives, Oral, Combined; Drug Combinations; Drug Interactions; Ethinyl Estradiol; Female; Fluorenes; Half-Life; Hepacivirus; Humans; Norgestrel; Sofosbuvir; Uridine Monophosphate | 2014 |
Sovaldi dilemma likely to get worse.
Topics: Antiviral Agents; Benzimidazoles; Drug Combinations; Fluorenes; Hepatitis C; Humans; Prescription Fees; Sofosbuvir; United States; Uridine Monophosphate | 2014 |
A combination of ledipasvir and sofosbuvir (Harvoni) for hepatitis C.
Topics: Antiviral Agents; Benzimidazoles; Drug Approval; Drug Combinations; Drug Interactions; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Sofosbuvir; United States; United States Food and Drug Administration; Uridine Monophosphate | 2014 |
Gilead's interferon-free HCV combo approved.
Topics: Benzimidazoles; Drug Approval; Drug Combinations; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Sofosbuvir; United States; United States Food and Drug Administration | 2014 |
Shorter treatments for hepatitis C: another step forward?
Topics: Antiviral Agents; Benzimidazoles; Female; Fluorenes; Furans; Hepatitis C, Chronic; Humans; Male; Quinolines; Ribavirin; RNA, Viral; Sofosbuvir; Thiophenes; Uridine Monophosphate | 2015 |
Ledipasvir/sofosbuvir regimens for chronic hepatitis C infection: Insights from a work productivity economic model from the United States.
Topics: Antiviral Agents; Benzimidazoles; Costs and Cost Analysis; Efficiency; Fluorenes; Hepatitis C, Chronic; Humans; Models, Economic; Sofosbuvir; United States; Uridine Monophosphate | 2015 |
Perspectives of fixed daily dose of sofosbuvir and ledipasvir for the treatment of chronic hepatitis C.
Topics: Antiviral Agents; Benzimidazoles; Coinfection; Drug Combinations; Fluorenes; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Randomized Controlled Trials as Topic; Recurrence; Sofosbuvir; Uridine Monophosphate | 2015 |
Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States.
Topics: Antiviral Agents; Benzimidazoles; Budgets; Cost-Benefit Analysis; Drug Costs; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Insurance, Health, Reimbursement; Interferon-alpha; Markov Chains; Patient-Specific Modeling; Quality-Adjusted Life Years; Sofosbuvir; United States; Uridine Monophosphate | 2015 |
Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir.
Topics: Antiviral Agents; Benzimidazoles; DNA, Viral; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Quality of Life; Sofosbuvir; Surveys and Questionnaires | 2015 |
Increased eligibility for treatment of chronic hepatitis C infection with shortened duration of therapy: Implications for access to care and elimination strategies in Canada.
Topics: Administration, Oral; Antiviral Agents; Benzimidazoles; Cost Savings; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Eligibility Determination; Fluorenes; Health Services Accessibility; Hepatitis C, Chronic; Humans; Mathematical Computing; Ontario; Reproducibility of Results; Research Design; Risk Assessment; Sofosbuvir; Time Factors; Treatment Outcome; Viral Load | 2015 |
Thousands of patients in England to get new hepatitis C drugs.
Topics: Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; England; Fluorenes; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Public Health; Pyrrolidines; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate; Valine | 2015 |
Direct antiviral agents for treatment-naïve patients with genotype 1 hepatitis C: A statistical model for comparing outcomes between real world and clinical trials.
Topics: Antiviral Agents; Bayes Theorem; Benzimidazoles; Clinical Trials as Topic; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Models, Statistical; Sofosbuvir | 2015 |
Emergence of hepatitis C virus NS5A L31V plus Y93H variant upon treatment failure of daclatasvir and asunaprevir is relatively resistant to ledipasvir and NS5B polymerase nucleotide inhibitor GS-558093 in human hepatocyte chimeric mice.
Topics: Animals; Antiviral Agents; Benzimidazoles; Carbamates; Drug Combinations; Drug Resistance, Multiple, Viral; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Hepatitis, Viral, Animal; Hepatocytes; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Pyrrolidines; Sofosbuvir; Sulfonamides; Transplantation Chimera; Treatment Failure; Valine | 2015 |
Effects of Viral Eradication With Ledipasvir and Sofosbuvir, With or Without Ribavirin, on Measures of Fatigue in Patients With Chronic Hepatitis C Virus Infection.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Biomarkers; Blood Chemical Analysis; Cytokines; Enzyme-Linked Immunosorbent Assay; Fatigue; Female; Fluorenes; Hepatitis C, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome | 2016 |
Acute liver failure during hepatitis C treatment with sofosbuvir and ledipasvir.
Topics: Acute-On-Chronic Liver Failure; Aged; Antiviral Agents; Benzimidazoles; End Stage Liver Disease; Fatal Outcome; Fluorenes; Hepacivirus; Hepatitis C; Humans; Male; Sofosbuvir | 2015 |
No scientific basis to restrict 8 weeks of treatment with ledipasvir/sofosbuvir to patients with hepatitis C virus RNA <6,000,000 IU/mL.
Topics: Antiviral Agents; Benzimidazoles; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; RNA, Viral; Sofosbuvir; Time Factors | 2016 |
Impact of eradicating hepatitis C virus on the work productivity of chronic hepatitis C (CH-C) patients: an economic model from five European countries.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Disease Eradication; Efficiency; Europe; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Models, Economic; Sofosbuvir; Surveys and Questionnaires; Young Adult | 2016 |
Cost-effectiveness of new antiviral regimens for treatment-naïve U.S. veterans with hepatitis C.
Topics: Aged; Antiviral Agents; Benzimidazoles; Cost-Benefit Analysis; Drug Combinations; Fluorenes; Hepatitis C, Chronic; Humans; Middle Aged; Quality-Adjusted Life Years; Sofosbuvir; United States; Veterans Health | 2016 |
Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Cost-Benefit Analysis; Decision Support Techniques; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Middle Aged; Quality-Adjusted Life Years; Severity of Illness Index; Sofosbuvir; Treatment Outcome; United States; Viral Load; Young Adult | 2016 |
Sofosbuvir-based regimens in clinical practice achieve SVR rates closer to clinical trials: results from ERCHIVES.
Topics: Aged; Antiviral Agents; Benzimidazoles; Comorbidity; Databases, Factual; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; United States | 2016 |
Simultaneous determination of ledipasvir, sofosbuvir and its metabolite in rat plasma by UPLC-MS/MS and its application to a pharmacokinetic study.
Topics: Animals; Antiviral Agents; Benzimidazoles; Chromatography, Liquid; Fluorenes; Male; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Sofosbuvir; Tandem Mass Spectrometry | 2016 |
Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older.
Topics: Age Factors; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Clinical Trials, Phase III as Topic; Cohort Studies; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluorenes; Follow-Up Studies; Genotype; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Patient Safety; Randomized Controlled Trials as Topic; Retrospective Studies; Ribavirin; Risk Assessment; Sex Factors; Sofosbuvir; Treatment Outcome | 2016 |
Daclatasvir + asunaprevir versus sofosbuvir/ledipasvir for hepatitis C genotype 1 in Japanese patients: an indirect comparison.
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Pyrrolidines; Sofosbuvir; Sulfonamides; Valine | 2016 |
Myo-pericarditis secondary to ledipasvir-sofosbuvir therapy.
Topics: Antiviral Agents; Benzimidazoles; Echocardiography; Electrocardiography; Fluorenes; Follow-Up Studies; Hepatitis C, Chronic; Humans; Male; Middle Aged; Myocarditis; Pericarditis; Sofosbuvir | 2016 |
Sofosbuvir-based treatment is safe and effective in patients with chronic hepatitis C infection and end stage renal disease: a case series.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Glomerular Filtration Rate; Hepacivirus; Hepatitis C, Chronic; Humans; Kidney Failure, Chronic; Male; Middle Aged; Ohio; Renal Dialysis; Simeprevir; Sofosbuvir; Sustained Virologic Response | 2016 |
In Vitro Antiviral Activity and Resistance Profile Characterization of the Hepatitis C Virus NS5A Inhibitor Ledipasvir.
Topics: Antiviral Agents; Benzimidazoles; Carrier Proteins; Cell Line, Tumor; Drug Combinations; Drug Resistance, Viral; Drug Synergism; Fluorenes; Genotype; HeLa Cells; Hepacivirus; Hepatitis C, Chronic; Humans; Intracellular Signaling Peptides and Proteins; Microbial Sensitivity Tests; Sofosbuvir; Viral Nonstructural Proteins | 2016 |
HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Imidazoles; Kinetics; Male; Middle Aged; Models, Theoretical; Pyrrolidines; Retrospective Studies; RNA, Viral; Simeprevir; Sofosbuvir; Time Factors; Valine | 2016 |
Patient-reported Outcomes in Asian Patients With Chronic Hepatitis C Treated With Ledipasvir and Sofosbuvir.
Topics: Antiviral Agents; Asia; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Patient Outcome Assessment; Quality of Life; Sofosbuvir; Surveys and Questionnaires | 2016 |
Efficacy and safety of sofosbuvir/ledipasvir for the treatment of patients with hepatitis C virus re-infection after liver transplantation.
Topics: Aged; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Benzimidazoles; Europe; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Transplantation; Male; Middle Aged; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome | 2016 |
Streptococcus salivarius spontaneous bacterial peritonitis in a HIV/HCV-co-infected patient treated with direct antiviral agents.
Topics: Anti-Bacterial Agents; Antiviral Agents; Bacterial Translocation; Benzimidazoles; Ceftriaxone; Coinfection; Disease Susceptibility; Esophageal and Gastric Varices; Esophagoscopy; Female; Fluorenes; Gastrointestinal Hemorrhage; Hepatitis C, Chronic; HIV Infections; Humans; Immunocompromised Host; Middle Aged; Peritonitis; Sofosbuvir; Streptococcus salivarius; Substance Abuse, Intravenous | 2017 |
Cost-effectiveness of currently recommended direct-acting antiviral treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the US.
Topics: 2-Naphthylamine; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Cyclopropanes; Drug Therapy, Combination; Female; Fibrosis; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Neoplasms; Macrocyclic Compounds; Male; Markov Chains; Middle Aged; Models, Econometric; Proline; Quality-Adjusted Life Years; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uracil; Valine | 2016 |
Interferon/Ribavirin-Free Antiviral Treatment in Septuagenarians and Octogenarians With Chronic Hepatitis C.
Topics: Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Fatigue; Female; Fluorenes; Hepatitis C, Chronic; Humans; Imidazoles; Male; Pruritus; Pyrrolidines; Recurrence; Simeprevir; Sleep Initiation and Maintenance Disorders; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2016 |
DAA-based antiviral treatment of patients with chronic hepatitis C in the pre- and postkidney transplantation setting.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Cohort Studies; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Immunosuppressive Agents; Kidney; Kidney Function Tests; Kidney Transplantation; Liver; Liver Transplantation; Male; Middle Aged; Postoperative Period; Preoperative Period; Pyrrolidines; Renal Dialysis; Renal Insufficiency; RNA, Viral; Simeprevir; Sofosbuvir; Valine | 2016 |
Hepatotoxicity and potential drug interaction with ledipasvir/sofosbuvir in HIV/HCV infected patients.
Topics: Antiviral Agents; Benzimidazoles; Chemical and Drug Induced Liver Injury; Drug Interactions; Drug Therapy, Combination; Fluorenes; Hepatitis C; HIV Infections; Humans; Sofosbuvir | 2016 |
Successful Re-treatment of Hepatitis C Virus in Patients Coinfected With HIV Who Relapsed After 12 Weeks of Ledipasvir/Sofosbuvir.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Coinfection; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Middle Aged; Recurrence; Ribavirin; Salvage Therapy; Sofosbuvir; Treatment Failure | 2016 |
Clearance of Hepatitis C Virus After Fixed-Dose Combination Ledipasvir/Sofosbuvir in an Adolescent Female With Decompensated Cirrhosis.
Topics: Adolescent; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Sofosbuvir; Viral Load | 2016 |
Direct Observed Therapy of Chronic Hepatitis C With Interferon-Free All-Oral Regimens at a Low-Threshold Drug Treatment Facility-a New Concept for Treatment of Patients With Borderline Compliance Receiving Opioid Substitution Therapy.
Topics: Adult; Antiviral Agents; Benzimidazoles; Carbamates; Coinfection; Directly Observed Therapy; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Liver Cirrhosis; Male; Medication Adherence; Middle Aged; Opiate Substitution Treatment; Opioid-Related Disorders; Pyrrolidines; Severity of Illness Index; Sofosbuvir; Substance Abuse Treatment Centers; Valine | 2016 |
Will Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus? An Economic Analysis Using Real-World Data.
Topics: Asian People; Benzimidazoles; China; Costs and Cost Analysis; Female; Fluorenes; Hepacivirus; Hepatitis C; Humans; Male; Markov Chains; Models, Economic; Sofosbuvir | 2016 |
Comparative effectiveness of ledipasvir/sofosbuvir ± ribavirin vs. ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in 6961 genotype 1 patients treated in routine medical practice.
Topics: 2-Naphthylamine; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Benzimidazoles; Black or African American; Carbamates; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; RNA, Viral; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Uracil; Valine; Young Adult | 2016 |
Quantification of sofosbuvir and ledipasvir in human plasma by UPLC-MS/MS method: Application to fasting and fed bioequivalence studies.
Topics: Adult; Antiviral Agents; Benzimidazoles; Chromatography, High Pressure Liquid; Fasting; Female; Fluorenes; Humans; Limit of Detection; Male; Middle Aged; Sofosbuvir; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Therapeutic Equivalency; Young Adult | 2016 |
Cost-Effectiveness of Genotype 1 Chronic Hepatitis C Virus Treatments in Patients Coinfected with Human Immunodeficiency Virus in the United States.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Cyclopropanes; Disease Progression; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Lactams, Macrocyclic; Liver Cirrhosis; Liver Neoplasms; Macrocyclic Compounds; Markov Chains; Middle Aged; Polyethylene Glycols; Proline; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; United States; Uracil; Valine | 2016 |
Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection.
Topics: Adult; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Sofosbuvir; Time Factors; Treatment Outcome | 2016 |
Retreatment efficacy and predictors of ledipasvir plus sofosbuvir to HCV genotype 1 in Japan.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Japan; Male; Middle Aged; Retreatment; Retrospective Studies; Sofosbuvir; Treatment Outcome; Young Adult | 2017 |
Ledipasvir and sofosbuvir for HCV infection in patients coinfected with HBV.
Topics: Aged; Antiviral Agents; Benzimidazoles; Coinfection; DNA, Viral; Drug Therapy, Combination; Female; Fluorenes; Hepatitis B; Hepatitis C; Humans; Male; Middle Aged; Pilot Projects; Sofosbuvir | 2016 |
Interferon-free regimens improve health-related quality of life and fatigue in HIV/HCV-coinfected patients with advanced liver disease: A retrospective study.
Topics: Antiviral Agents; Austria; Benzimidazoles; Carbamates; Coinfection; Fatigue; Female; Fluorenes; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Quality of Life; Retrospective Studies; Severity of Illness Index; Sofosbuvir; Treatment Outcome; Valine | 2016 |
Adherence to treatment of chronic hepatitis C: from interferon containing regimens to interferon and ribavirin free regimens.
Topics: Antiviral Agents; Benzimidazoles; Clinical Trials, Phase III as Topic; Female; Fluorenes; Genotype; Hepatitis C, Chronic; Humans; Interferons; Male; Medication Adherence; Middle Aged; Multicenter Studies as Topic; Patient Reported Outcome Measures; Ribavirin; Sofosbuvir | 2016 |
NS5A resistance leading to failure of 24-week therapy with sofosbuvir/ledipasvir and ribavirin for the treatment of hepatitis C genotype 1a infection in a HIV-1 co-infected patient.
Topics: Antiviral Agents; Benzimidazoles; Drug Resistance, Viral; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Liver Cirrhosis; Male; Middle Aged; Mutation, Missense; Ribavirin; Sofosbuvir; Treatment Failure; Viral Nonstructural Proteins | 2016 |
Nephrotoxicity Associated with Concomitant Use of Ledipasvir-Sofosbuvir and Tenofovir in a Patient with Hepatitis C Virus and Human Immunodeficiency Virus Coinfection.
Topics: Antiviral Agents; Benzimidazoles; Coinfection; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C; HIV Infections; Humans; Kidney; Middle Aged; Sofosbuvir; Tenofovir | 2016 |
A Rapid and Optimized LC-MS/MS Method for the Simultaneous Extraction and Determination of Sofosbuvir and Ledipasvir in Human Plasma.
Topics: Benzimidazoles; Chromatography, Liquid; Fluorenes; Humans; Molecular Structure; Sofosbuvir; Tandem Mass Spectrometry | 2016 |
Successful Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir and Ledipasvir in Renal Transplant Recipients.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluorenes; Follow-Up Studies; Hepatitis C, Chronic; Humans; Kidney Transplantation; Male; Middle Aged; Postoperative Complications; Retrospective Studies; Sofosbuvir; Treatment Outcome | 2017 |
Evaluation of proton pump inhibitor use on treatment outcomes with ledipasvir and sofosbuvir in a real-world cohort study.
Topics: Antiviral Agents; Benzimidazoles; Cohort Studies; Drug Interactions; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Proton Pump Inhibitors; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome | 2016 |
Quality of life of Japanese patients with chronic hepatitis C treated with ledipasvir and sofosbuvir.
Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Japan; Male; Middle Aged; Quality of Life; Ribavirin; Sofosbuvir; Surveys and Questionnaires | 2016 |
Hepatitis B reactivation in a chronic hepatitis C patient treated with ledipasvir and sofosbuvir: A case report.
Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Fluorenes; Hepatitis B; Hepatitis C, Chronic; Humans; Recurrence; Sofosbuvir; Time Factors; Treatment Outcome | 2017 |
Cost-utility analysis of ledipasvir/sofosbuvir for the treatment of genotype 1 chronic hepatitis C in Japan.
Topics: Antiviral Agents; Benzimidazoles; Cost-Benefit Analysis; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Sofosbuvir | 2017 |
Curing HCV infection with 4 weeks-regimen of sofosbuvir and ledipasvir: To be remembered.
Topics: Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepacivirus; Hepatitis C; Humans; Middle Aged; Sofosbuvir | 2016 |
Optimal timing for hepatitis C therapy in US patients eligible for liver transplantation: a cost-effectiveness analysis.
Topics: Antiviral Agents; Benzimidazoles; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Disease Progression; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Quality-Adjusted Life Years; Ribavirin; Sofosbuvir; United States | 2016 |
Curing the historically incurable: treatment success with ledipasvir/sofosbuvir for chronic hepatitis C virus in a heavily treatment-experienced individual.
Topics: Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Middle Aged; Sofosbuvir; Treatment Outcome | 2016 |
Second-generation direct-acting-antiviral hepatitis C virus treatment: Efficacy, safety, and predictors of SVR12.
Topics: Adult; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Hypertension, Portal; Imidazoles; Liver Cirrhosis; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Treatment Outcome; Valine | 2016 |
Community-based real-world treatment outcomes of sofosbuvir/ledipasvir in Asians with chronic hepatitis C virus genotype 6 in the United States.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Asian; Benzimidazoles; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; United States; Young Adult | 2017 |
Sofosbuvir-Containing Regimens for Chronic Hepatitis C Are Successful in the Safety-Net Population: A Real-World Experience.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Carbamates; Cohort Studies; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Logistic Models; Male; Medication Adherence; Middle Aged; Multivariate Analysis; Polyethylene Glycols; Pyrrolidines; Retrospective Studies; Ribavirin; San Francisco; Simeprevir; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine; Vulnerable Populations; Young Adult | 2016 |
High cost of new drugs.
Topics: Antiviral Agents; Benzimidazoles; Cost-Benefit Analysis; Costs and Cost Analysis; Drug Costs; Drug Industry; Fluorenes; Hepatitis C; Humans; Sofosbuvir; United Kingdom | 2016 |
Detection of Occult Hepatitis C Virus Infection in Patients Who Achieved a Sustained Virologic Response to Direct-Acting Antiviral Agents for Recurrent Infection After Liver Transplantation.
Topics: Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Benzimidazoles; Carbamates; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Limit of Detection; Liver Transplantation; Male; Middle Aged; Prospective Studies; Pyrrolidines; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Ribavirin; RNA, Viral; Simeprevir; Sofosbuvir; Sustained Virologic Response; Valine; Viral Load; Virus Replication | 2017 |
The levels of monoamine neurotransmitters and measures of mental and emotional health in HCV patients treated with ledipasvir (LDV) and sofosbuvir (SOF) with or without ribavirin (RBV).
Topics: Affective Symptoms; Antiviral Agents; Benzimidazoles; Biomarkers; Cytokines; Female; Fluorenes; Hepatitis C, Chronic; Humans; Male; Mental Disorders; Middle Aged; Neurotransmitter Agents; Retrospective Studies; Ribavirin; Sofosbuvir | 2016 |
NS5A resistance-associated variants undermine the effectiveness of ledipasvir and sofosbuvir for cirrhotic patients infected with HCV genotype 1b.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Cohort Studies; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Risk Factors; Sex Factors; Sofosbuvir; Sustained Virologic Response; Treatment Failure; Viral Nonstructural Proteins; Young Adult | 2017 |
Hepatitis C Treatment With Direct-Acting Antivirals in Kidney Transplant: Preliminary Results From a Multicenter Study.
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C; Humans; Imidazoles; Immunosuppression Therapy; Kidney Transplantation; Lactams, Macrocyclic; Macrocyclic Compounds; Postoperative Complications; Proline; Prospective Studies; Pyrrolidines; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Spain; Sulfonamides; Treatment Outcome; Valine | 2016 |
Treatment of hepatitis C virus recurrence after transplantation with sofosbuvir/ledipasvir: The role of ribavirin.
Topics: Aged; Antiviral Agents; Benzimidazoles; Drug Interactions; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Immunocompromised Host; Immunosuppressive Agents; Liver Transplantation; Male; Middle Aged; Recurrence; Retrospective Studies; Ribavirin; Sofosbuvir | 2017 |
Outcome of Combination Therapy with Sofosbuvir and Ledipasvir for Chronic Type C Liver Disease.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Combinations; Female; Fluorenes; Hepatitis C, Chronic; Humans; Male; Middle Aged; Sofosbuvir; Treatment Outcome | 2017 |
Genotype specific peripheral lipid profile changes with hepatitis C therapy.
Topics: Aged; Alanine Transaminase; Antiviral Agents; Benzimidazoles; Cholesterol; Cohort Studies; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Triglycerides | 2016 |
Cost-Effectiveness of Treating Hepatitis C with Sofosbuvir/Ledipasvir in Germany.
Topics: Adult; Antiviral Agents; Benzimidazoles; Cost-Benefit Analysis; Fluorenes; Genotype; Germany; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Markov Chains; Middle Aged; Models, Theoretical; Public Health; Quality of Life; Quality-Adjusted Life Years; Sensitivity and Specificity; Sofosbuvir | 2017 |
Successful treatment of donor-derived hepatitis C viral infection in three transplant recipients from a donor at increased risk for bloodborne pathogens.
Topics: Acetaminophen; Adult; Allografts; Antiviral Agents; Benzimidazoles; Blood-Borne Pathogens; Chemical and Drug Induced Liver Injury; Disease Transmission, Infectious; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C; Humans; Kidney Failure, Chronic; Kidney Transplantation; Liver Transplantation; Male; Middle Aged; Polymerase Chain Reaction; Ribavirin; RNA, Viral; Sofosbuvir; Transplant Recipients; Viral Load | 2017 |
Eight- or 12-Week Treatment of Hepatitis C with Ledipasvir/Sofosbuvir: Real-World Experience in a Large Integrated Health System.
Topics: Antiviral Agents; Benzimidazoles; Delivery of Health Care, Integrated; Fluorenes; Hepatitis C; Humans; Sofosbuvir; Time Factors | 2017 |
Sofosbuvir plus ledipasvir for recurrent hepatitis C in liver transplant recipients.
Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Transplantation; Sofosbuvir | 2017 |
Ledipasvir-sofosbuvir and sofosbuvir plus ribavirin in patients with chronic hepatitis C and bleeding disorders.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Combinations; Female; Fluorenes; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; Sofosbuvir; Treatment Outcome; Young Adult | 2017 |
Treatment with sofosbuvir and ledipasvir without ribavirin for 12 weeks is highly effective for recurrent hepatitis C virus genotype 1b infection after living donor liver transplantation: a Japanese multicenter experience.
Topics: Aged; Antiviral Agents; Benzimidazoles; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Japan; Liver Transplantation; Living Donors; Male; Middle Aged; Postoperative Period; Recurrence; Ribavirin; Sofosbuvir; Sustained Virologic Response; Viral Nonstructural Proteins | 2017 |
Identification of Predictors for Treatment Failure in Hepatitis C Virus Patients Treated With Ledipasvir and Sofosbuvir.
Topics: Aged; Antiviral Agents; Benzimidazoles; Case-Control Studies; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Odds Ratio; Retrospective Studies; Sofosbuvir; Treatment Failure; Treatment Outcome; Viral Load | 2017 |
Three patients treated with sofosbuvir plus ledipasvir for recurrent hepatitis C after liver transplantation.
Topics: Aged; Antiviral Agents; Benzimidazoles; Cyclosporine; Drug Interactions; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Liver Transplantation; Male; Middle Aged; Recurrence; RNA, Viral; Sofosbuvir; Viral Load | 2017 |
[Debut in diabetic patients with hepatitis C treatment with ledipasvir/ sofosbuvir (Harvoni®)].
Topics: Antiviral Agents; Benzimidazoles; Diabetes Complications; Fluorenes; Hepatitis C, Chronic; Humans; Male; Middle Aged; Sofosbuvir | 2017 |
Comparison of on-treatment HCV RNA during direct antiviral therapy using two different COBAS TaqMan HCV assays.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Automation, Laboratory; Benzimidazoles; Drug Monitoring; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Middle Aged; Molecular Diagnostic Techniques; RNA, Viral; Sofosbuvir; Viral Load; Young Adult | 2017 |
Hepatitis B reactivation in chronic hepatitis C patients during treatment with ledipasvir and sofosbuvir.
Topics: Benzimidazoles; Coinfection; Fluorenes; Hepatitis B; Hepatitis B virus; Hepatitis C, Chronic; HIV Infections; Humans; Sofosbuvir | 2018 |
Author reply to: Hepatitis B reactivation in chronic hepatitis C patients during treatment with ledipasvir and sofosbuvir.
Topics: Benzimidazoles; Coinfection; Fluorenes; Hepatitis B; Hepatitis B virus; Hepatitis C, Chronic; HIV Infections; Humans; Sofosbuvir | 2018 |
Retreatment with sofosbuvir, ledipasvir, and add-on ribavirin for patients who failed daclatasvir and asunaprevir combination therapy.
Topics: Aged; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Prospective Studies; Pyrrolidines; Retreatment; Ribavirin; Sofosbuvir; Sulfonamides; Treatment Outcome; Valine | 2017 |
Spectrophotometric Methods for Simultaneous Determination of Sofosbuvir and Ledipasvir (HARVONI Tablet): Comparative Study with Two Generic Products.
Topics: Benzimidazoles; Drugs, Generic; Fluorenes; Sofosbuvir; Tablets; Therapeutic Equivalency; Uridine Monophosphate | 2017 |
Transplantation of kidneys from hepatitis C-positive donors into hepatitis C virus-infected recipients followed by early initiation of direct acting antiviral therapy: a single-center retrospective study.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Donor Selection; Drug Therapy, Combination; Female; Fluorenes; Follow-Up Studies; Hepatitis C, Chronic; Humans; Imidazoles; Kidney Failure, Chronic; Kidney Transplantation; Male; Middle Aged; Postoperative Care; Pyrrolidines; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Tissue Donors; Treatment Outcome; Valine | 2017 |
Sofosbuvir-based treatment is safe and effective in Indian hepatitis C patients on maintenance haemodialysis: A retrospective study.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; India; Kidney Diseases; Male; Middle Aged; Pyrrolidines; Renal Dialysis; Retrospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Time Factors; Treatment Outcome; Valine; Viral Load | 2018 |
Acute fulminant hepatitis B during hepatitis C virus therapy with direct-acting antivirals in a patient co-infected with HIV.
Topics: Anti-HIV Agents; Antiviral Agents; Benzimidazoles; Coinfection; Drug Substitution; Fatal Outcome; Fluorenes; Hepacivirus; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Liver Failure, Acute; Male; Middle Aged; Oligopeptides; Ribavirin; Sofosbuvir; Virus Activation | 2017 |
Interferon free antiviral treatment of chronic hepatitis C in patients affected by β-thalassemia major.
Topics: Adult; Antiviral Agents; Benzimidazoles; Benzoates; beta-Thalassemia; Cryoglobulinemia; Deferasirox; Deferoxamine; Elasticity Imaging Techniques; Female; Ferritins; Fluorenes; Hepatitis C, Chronic; Humans; Iron Chelating Agents; Iron Overload; Liver Cirrhosis; Male; Quality of Life; Sofosbuvir; Triazoles; Viral Load | 2017 |
Ventricular Tachycardia as a Complication of Ledipasvir and Sofosbuvir Treatment for HCV Infection.
Topics: Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C; Humans; Risk Factors; Sofosbuvir; Tachycardia, Ventricular | 2017 |
Treatment of HCV infection in liver transplant recipients with ledipasvir and sofosbuvir without ribavirin.
Topics: Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Transplantation; Logistic Models; Male; Middle Aged; Retrospective Studies; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Viral Load | 2017 |
Sustained virological response in a treatment-experienced patient with hepatitis C virus genotype 6 infection: Follow-up on a reported case.
Topics: Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Fluorenes; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Ribavirin; Sofosbuvir; Sustained Virologic Response; Viral Load | 2017 |
Co-administration of tenofovir plus protease inhibitor based antiretroviral therapy during sofosbuvir/ledipasvir treatment for HCV infection: Much Ado About Nothing?
Topics: Antiviral Agents; Benzimidazoles; Drug Administration Schedule; Drug Therapy, Combination; Evidence-Based Medicine; Fluorenes; Hepatitis C; Humans; Sofosbuvir; Tenofovir; Treatment Outcome | 2017 |
Real-World Experiences with the Combination Treatment of Ledipasvir plus Sofosbuvir for 12 Weeks in HCV Genotype 1-Infected Japanese Patients: Achievement of a Sustained Virological Response in Previous Users of Peginterferon plus Ribavirin with HCV NS3/4
Topics: Aged; Antiviral Agents; Asian People; Benzimidazoles; Carrier Proteins; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon-alpha; Interferons; Interleukins; Intracellular Signaling Peptides and Proteins; Japan; Male; Middle Aged; Polyethylene Glycols; Polymorphism, Single Nucleotide; Recombinant Proteins; Retrospective Studies; Ribavirin; RNA, Viral; Sofosbuvir; Treatment Outcome; Viral Nonstructural Proteins | 2017 |
Reply to Ozaras et al.
Topics: Benzimidazoles; Fluorenes; Hepacivirus; Hepatitis B virus; Humans; Sofosbuvir | 2017 |
Reactivation of Hepatitis B Virus Following Treatment of Hepatitis C Virus Infection in Coinfected Patients.
Topics: Benzimidazoles; Coinfection; Fluorenes; Hepacivirus; Hepatitis B virus; Hepatitis C; HIV Infections; Humans; Sofosbuvir | 2017 |
Efficacy and Safety of Ledipasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C in Persons With Sickle Cell Disease.
Topics: Adult; Anemia, Sickle Cell; Antiviral Agents; Benzimidazoles; Drug Combinations; Female; Fluorenes; Hepatitis C, Chronic; Humans; Male; Middle Aged; Sofosbuvir; Young Adult | 2017 |
Effectiveness and safety of ledipasvir/sofosbuvir±ribavirin in the treatment of HCV infection: The real-world HARVEST study.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Follow-Up Studies; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Ribavirin; Safety; Sofosbuvir; Treatment Outcome | 2017 |
Potential risk of HBV reactivation in patients with resolved HBV infection undergoing direct-acting antiviral treatment for HCV.
Topics: Aged; Antiviral Agents; Benzimidazoles; DNA, Viral; Female; Fluorenes; Hepacivirus; Hepatitis B; Hepatitis B Antibodies; Hepatitis B virus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Ribavirin; Risk Assessment; Risk Factors; Sofosbuvir; Time Factors; Treatment Outcome; Virus Activation | 2018 |
Successful treatment of sexually acquired acute HCV reinfection with ledipasvir/sofosbuvir in a HIV-infected patient.
Topics: Antiviral Agents; Benzimidazoles; Coinfection; Fluorenes; Hepatitis C, Chronic; HIV Infections; Homosexuality, Male; Humans; Male; Middle Aged; Sofosbuvir; Treatment Outcome | 2017 |
The elderly and direct antiviral agents: Constraint or challenge?
Topics: Aged; Antiviral Agents; Benzimidazoles; Carbamates; Drug Interactions; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Italy; Logistic Models; Male; Pyrrolidines; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Valine | 2017 |
Effectiveness of 8- or 12-weeks of ledipasvir and sofosbuvir in real-world treatment-naïve, genotype 1 hepatitis C infected patients.
Topics: Aged; Antiviral Agents; Benzimidazoles; Cohort Studies; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Retrospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome | 2017 |
Chemical Analysis of Counterfeit Hepatitis C Drug Found in Japan.
Topics: Antiviral Agents; Benzimidazoles; Chromatography, Liquid; Counterfeit Drugs; Drugs, Chinese Herbal; Ephedrine; Fluorenes; Gas Chromatography-Mass Spectrometry; Glycyrrhizic Acid; Hepatitis C; Japan; Magnetic Resonance Spectroscopy; Mass Spectrometry; Sofosbuvir; Tablets; Uridine Monophosphate; Vitamins | 2017 |
Successful treatment of chronic hepatitis C with ground ledipasvir/sofosbuvir in a patient with Crohn's disease and short bowel syndrome.
Topics: Antiviral Agents; Benzimidazoles; Crohn Disease; Fluorenes; Hepatitis C, Chronic; Humans; Short Bowel Syndrome; Sofosbuvir | 2018 |
A new innovative spectrophotometric method for the simultaneous determination of sofosbuvir and ledipasvir.
Topics: Benzimidazoles; Calibration; Chromatography, High Pressure Liquid; Dosage Forms; Fluorenes; Limit of Detection; Reproducibility of Results; Sofosbuvir; Spectrophotometry, Ultraviolet | 2018 |
A different perspective on sofosbuvir-ledipasvir treatment of patients with HCV genotype 1b cirrhosis: The ital-c network study.
Topics: Aged; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2018 |
Regression of liver fibrosis over a 24-week period after completing direct-acting antiviral therapy in patients with chronic hepatitis C receiving care within the national hepatitis C elimination program in Georgia: results of hepatology clinic HEPA exper
Topics: Adult; Antiviral Agents; Benzimidazoles; Disease Eradication; Drug Therapy, Combination; Elasticity Imaging Techniques; Female; Fluorenes; Genotype; Georgia (Republic); Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; Recombinant Proteins; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2017 |
Effect of Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir and Ledipasvir/Sofosbuvir Regimens on Survival Compared With Untreated Hepatitis C Virus-Infected Persons: Results From ERCHIVES.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Kaplan-Meier Estimate; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Propensity Score; Proportional Hazards Models; Ritonavir; Sofosbuvir; Sulfonamides; Survival Rate; Sustained Virologic Response; Uracil; Valine | 2017 |
Spectroflurimetric estimation of the new antiviral agent ledipasvir in presence of sofosbuvir.
Topics: Antiviral Agents; Benzimidazoles; Buffers; Drug Compounding; Fluorenes; Hydrogen-Ion Concentration; Limit of Detection; Sofosbuvir; Solvents; Spectrometry, Fluorescence; Time Factors | 2018 |
Ledipasvir and Sofosbuvir for untreated HCV genotype 1 infection in end stage renal disease patients: A prospective observational study.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Kidney Failure, Chronic; Male; Middle Aged; Prospective Studies; Renal Dialysis; Sofosbuvir; Treatment Outcome; Young Adult | 2018 |
Sofosbuvir-based Interferon-Free Direct Acting Antiviral Regimens for Heart Transplant Recipients With Chronic Hepatitis C Virus Infection.
Topics: Adult; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Fluorenes; Heart Transplantation; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Prospective Studies; Pyrrolidines; Sofosbuvir; Sustained Virologic Response; Transplant Recipients; Treatment Outcome; Valine; Young Adult | 2018 |
Impact of ledipasvir/sofosbuvir on the work productivity of genotype 1 chronic hepatitis C patients in Asia.
Topics: Absenteeism; Antiviral Agents; Asia; Benzimidazoles; Efficiency; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Sofosbuvir; Treatment Outcome; Work Performance | 2018 |
Sofosbuvir (SOF) Suppresses Ledipasvir (LDV)-resistant Mutants during SOF/LDV Combination Therapy against Genotype 1b Hepatitis C Virus (HCV).
Topics: Antiviral Agents; Benzimidazoles; Cell Line; Combined Modality Therapy; Drug Interactions; Drug Resistance, Viral; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Models, Theoretical; Sofosbuvir; Uridine Monophosphate | 2017 |
Treatment of Acute Hepatitis C With Ledipasvir and Sofosbuvir in Patients With Hematological Malignancies Allows Early Re-start of Chemotherapy.
Topics: Adult; Antineoplastic Agents; Antiviral Agents; Benzimidazoles; Drug Therapy; Female; Fluorenes; Hematologic Neoplasms; Hepatitis C; Humans; Male; Middle Aged; Sofosbuvir | 2018 |
The influence of immunosuppressants on direct-acting antiviral therapy is dependent on the hepatitis C virus genotype.
Topics: Antiviral Agents; Benzimidazoles; Calcineurin Inhibitors; Carbamates; Cell Line; Cyclosporine; Everolimus; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Immunosuppressive Agents; Liver Transplantation; Pyrrolidines; Sirolimus; Sofosbuvir; Valine; Virus Replication | 2018 |
Use of a hepatitis C virus (HCV) RNA-positive donor in a treated HCV RNA-negative liver transplant recipient.
Topics: Antiviral Agents; Benzimidazoles; Carcinoma, Hepatocellular; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Tissue Donors; Transplant Recipients; Viral Load | 2018 |
Real-world effectiveness of 8-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C.
Topics: Aged; Aged, 80 and over; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Male; Middle Aged; Sofosbuvir | 2018 |
Sofosbuvir, pegylated interferon, and ribavirin for retreatment of hepatitis C virus genotype 1b following sofosbuvir and ledipasvir failure.
Topics: Adult; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Male; Polyethylene Glycols; Recombinant Proteins; Retreatment; Ribavirin; Sofosbuvir | 2018 |
Long-term follow-up of ribavirin-free DAA-based treatment in HCV recurrence after orthotopic liver transplantation.
Topics: Aged; Antiviral Agents; Austria; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Fluorenes; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Pyrrolidines; Recurrence; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Valine | 2018 |
Uptake of direct-acting antiviral treatment for chronic hepatitis C in Australia.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Australia; Benzimidazoles; Carbamates; Drug Utilization; Female; Fluorenes; Hepatitis C, Chronic; Humans; Imidazoles; Longitudinal Studies; Male; Middle Aged; Pyrrolidines; Sofosbuvir; Valine; Young Adult | 2018 |
Comparison between core-shell and totally porous particle stationary phases for fast and green LC determination of five hepatitis-C antiviral drugs.
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Chromatography, High Pressure Liquid; Fluorenes; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Imidazoles; Molecular Conformation; Particle Size; Porosity; Pyrrolidines; Simeprevir; Sofosbuvir; Surface Properties; Valine | 2018 |
Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Europe; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Longitudinal Studies; Male; Middle Aged; North America; Prospective Studies; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Young Adult | 2018 |
Directly observed therapy of chronic hepatitis C with ledipasvir/sofosbuvir in people who inject drugs at risk of nonadherence to direct-acting antivirals.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Directly Observed Therapy; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Medication Adherence; Middle Aged; Sofosbuvir; Substance Abuse, Intravenous; Sustained Virologic Response; Treatment Outcome; Young Adult | 2018 |
Chemometric simultaneous determination of Sofosbuvir and Ledipasvir in pharmaceutical dosage form.
Topics: Benzimidazoles; Chromatography, High Pressure Liquid; Drug Compounding; Fluorenes; Least-Squares Analysis; Sofosbuvir; Spectrophotometry; Wavelet Analysis | 2018 |
Safety and efficacy of anti-PD-1 therapy for metastatic melanoma and non-small-cell lung cancer in patients with viral hepatitis: a case series.
Topics: Aged; Antibodies, Monoclonal, Humanized; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Fluorenes; Hepatitis B; Hepatitis C; Humans; Interferons; Lung Neoplasms; Male; Melanoma; Middle Aged; Nivolumab; Programmed Cell Death 1 Receptor; Skin Neoplasms; Sofosbuvir | 2018 |
Nonstructural protein 5A/P32 deletion after failure of ledipasvir/sofosbuvir in hepatitis C virus genotype 1b infection.
Topics: Aged; Antiviral Agents; Benzimidazoles; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Male; Sequence Deletion; Sofosbuvir; Treatment Failure; Viral Nonstructural Proteins | 2018 |
Preliminary experience with sofosbuvir-based treatment regimens for patients dependent on hemodialysis.
Topics: Antiviral Agents; Benzimidazoles; Disease Progression; Drug Administration Schedule; Drug Therapy, Combination; Fluorenes; Hepatitis C; Humans; Kidney Failure, Chronic; Renal Dialysis; Sofosbuvir | 2018 |
Prevalence and impact of baseline resistance-associated substitutions on the efficacy of ledipasvir/sofosbuvir or simeprevir/sofosbuvir against GT1 HCV infection.
Topics: Aged; Antiviral Agents; Benzimidazoles; Clinical Trials as Topic; Drug Resistance, Viral; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Prevalence; Simeprevir; Sofosbuvir | 2018 |
No Difference in Effectiveness of 8 vs 12 Weeks of Ledipasvir and Sofosbuvir for Treatment of Hepatitis C in Black Patients.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Black People; California; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Sofosbuvir; Time Factors; Treatment Outcome | 2018 |
Real-world efficacy and safety of ledipasvir and sofosbuvir in patients with hepatitis C virus genotype 1 infection: a nationwide multicenter study by the Japanese Red Cross Liver Study Group.
Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antiviral Agents; Benzimidazoles; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Japan; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Polymorphism, Single Nucleotide; Prospective Studies; Red Cross; Retrospective Studies; Risk; Sofosbuvir; Sustained Virologic Response; Treatment Failure; Viral Nonstructural Proteins; Young Adult | 2018 |
Direct-acting antivirals response in an acute nosocomial genotype 1b HCV outbreak.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Cross Infection; Disease Outbreaks; Female; Fluorenes; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Time Factors | 2018 |
Generic sofosbuvir-based direct-acting antivirals in hepatitis C virus-infected patients with chronic kidney disease.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Drugs, Generic; Female; Fluorenes; Genotype; Glomerular Filtration Rate; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; India; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Renal Dialysis; Renal Insufficiency, Chronic; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine; Viral Load; Young Adult | 2018 |
Incidence of Acute Kidney Injury in Patients Coinfected with HIV and Hepatitis C Virus Receiving Tenofovir Disoproxil Fumarate and Ledipasvir/Sofosbuvir in a Real-World, Urban, Ryan White Clinic.
Topics: Acute Kidney Injury; Adolescent; Adult; Aged; Antiviral Agents; Benzimidazoles; Coinfection; Female; Fluorenes; Georgia; Hepatitis C, Chronic; HIV Infections; Humans; Incidence; Male; Middle Aged; Retrospective Studies; Reverse Transcriptase Inhibitors; Risk Factors; Sofosbuvir; Tenofovir; Young Adult | 2018 |
Real-world data on antiviral treatments for hepatitis C virus infections: Can we define intention to treat or per protocol analyses?
Topics: Antiviral Agents; Benzimidazoles; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Intention to Treat Analysis; Sofosbuvir | 2018 |
Editorial: retreatment of DAA-failures-no problem at all?
Topics: Antiviral Agents; Benzimidazoles; Fluorenes; Genotype; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Retreatment; Ribavirin; Simeprevir; Sofosbuvir | 2018 |
Significance of NS5B Substitutions in Genotype 1b Hepatitis C Virus Evaluated by Bioinformatics Analysis.
Topics: Amino Acid Substitution; Antiviral Agents; Benzimidazoles; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Japan; Molecular Dynamics Simulation; Mutation, Missense; Protein Conformation; Recurrence; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Viral Nonstructural Proteins | 2018 |
Successful DAA-Based Treatment of Hcv-Related Fibrosing Cholestatic Hepatitis After Liver Transplantation Due to a Fulminant Liver Failure.
Topics: Adult; Antiviral Agents; Benzimidazoles; Diagnosis, Differential; Drug Therapy, Combination; Fluorenes; Hepatitis C, Chronic; Humans; Jaundice, Obstructive; Liver Failure, Acute; Liver Transplantation; Male; Postoperative Complications; Sofosbuvir | 2018 |
The "real-world" efficacy and safety of DAAs for the treatment of HCV patients throughout Japan.
Topics: Benzimidazoles; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Japan; Red Cross; Sofosbuvir | 2018 |
Editorial: is sofosbuvir-based therapy suitable for patients with advanced chronic kidney disease?
Topics: 2-Naphthylamine; Anilides; Benzimidazoles; Carbamates; Cyclopropanes; Fluorenes; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Renal Insufficiency, Chronic; Ritonavir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uracil; Valine | 2018 |
Remission of chronic inflammatory demyelinating polyneuropathy after hepatitis C virus eradication with sofosbuvir and ledipasvir therapy.
Topics: Antiviral Agents; Benzimidazoles; Fluorenes; Hepacivirus; Hepatitis C; Humans; Immunoglobulins, Intravenous; Immunologic Factors; Male; Middle Aged; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Recurrence; Sofosbuvir | 2018 |
Earth-friendly spectrophotometric methods for simultaneous determination of ledipasvir and sofosbuvir: Application to average content and uniformity of dosage unit testing.
Topics: Benzimidazoles; Fluorenes; Green Chemistry Technology; Limit of Detection; Linear Models; Reproducibility of Results; Sofosbuvir; Spectrophotometry; Tablets; Uridine Monophosphate | 2018 |
Development of a highly sensitive high-performance thin-layer chromatography method for the screening and simultaneous determination of sofosbuvir, daclatasvir, and ledipasvir in their pure forms and their different pharmaceutical formulations.
Topics: Benzimidazoles; Carbamates; Chromatography, Thin Layer; Drug Compounding; Fluorenes; Imidazoles; Pyrrolidines; Sofosbuvir; Valine | 2018 |
High efficacy of generic and brand direct acting antivirals in treatment of chronic hepatitis C.
Topics: Adult; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Drugs, Generic; Egypt; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2018 |
Sofosbuvir based regimens in the treatment of chronic hepatitis C genotype 1 infection in African-American patients: a community-based retrospective cohort study.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Black or African American; Carbamates; Community Health Centers; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response | 2018 |
Treatment of Chronic Hepatitis C Infection with Direct Acting Antivirals in Adolescents with Thalassemia Major.
Topics: Adolescent; Antiviral Agents; Benzimidazoles; beta-Thalassemia; Carbamates; Child; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Prospective Studies; Pyrrolidines; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine; Viral Load | 2019 |
Sofosbuvir with NS5A inhibitors in hepatitis C virus infection with severe renal insufficiency.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Carbamates; Female; Fluorenes; Genotype; Glomerular Filtration Rate; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Renal Insufficiency; Sofosbuvir; Treatment Outcome; Valine; Viral Nonstructural Proteins; Young Adult | 2018 |
Potential Overestimation of Racial Disparities in Response to the 8-Week Ledipasvir/Sofosbuvir Regimen for Hepatitis C Virus Genotype 1 Infection.
Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Fluorenes; Genotype; Health Status Disparities; Hepacivirus; Hepatitis C; Humans; Sofosbuvir | 2018 |
Findings from a large Asian chronic hepatitis C real-life study.
Topics: Adult; Antiviral Agents; Asia; Benzimidazoles; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Ribavirin; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2018 |
Acute changes in cardiac function by direct acting antiviral therapy for hepatitis C-infected patients with thalassemia.
Topics: Adolescent; Adult; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Heart; Heart Diseases; Heart Function Tests; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Prospective Studies; Sofosbuvir; Thalassemia; Young Adult | 2019 |
No clinical impact of HCV RNA determination at the end of treatment in patients receiving directly acting antivirals.
Topics: Antiviral Agents; Benzimidazoles; Fluorenes; Hepatitis C; Humans; RNA; Sofosbuvir | 2018 |
The role of anti-HBs in hepatitis B reactivation during direct-acting antiviral therapy for chronic hepatitis C.
Topics: Antiviral Agents; Benzimidazoles; DNA, Viral; Female; Fluorenes; Hepacivirus; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Core Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Prospective Studies; Sofosbuvir; Viremia; Virus Activation | 2018 |
Using telehealth to improve access to hepatitis C treatment in the direct-acting antiviral therapy era.
Topics: Adult; Aged; Antiviral Agents; Australia; Benzimidazoles; Carbamates; Delivery of Health Care; Female; Fluorenes; Health Services Accessibility; Hepatitis C; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Sofosbuvir; Telemedicine; Treatment Outcome; Valine | 2020 |
Recovery of natural killer cells is mainly in post-treatment period in chronic hepatitis C patients treated with sofosbuvir plus ledipasvir.
Topics: Adult; Antiviral Agents; Benzimidazoles; Case-Control Studies; Cohort Studies; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunity, Innate; Killer Cells, Natural; Male; Middle Aged; Sofosbuvir; Sustained Virologic Response | 2018 |
Sofosbuvir-Based Therapy in Hepatitis C Virus-Infected Cancer Patients: A Prospective Observational Study.
Topics: Aged; Antiviral Agents; Benzimidazoles; Breast Neoplasms; Carbamates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Fluorenes; Head and Neck Neoplasms; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Interferons; Liver Neoplasms; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Neoplasms; Polyethylene Glycols; Prospective Studies; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response; Valine | 2019 |
Successful direct-acting antiviral treatment of three patients with genotype 2/1 recombinant hepatitis C virus.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Pyrrolidines; RNA; Sofosbuvir; Sulfonamides; Valine | 2019 |
Simultaneous quantification of simeprevir sodium: A hepatitis C protease inhibitor in binary and ternary mixtures with sofosbuvir and/or ledipasvir utilizing direct and H-point standard addition strategies.
Topics: Antiviral Agents; Artifacts; Benzimidazoles; Calibration; Complex Mixtures; Fluorenes; Hepacivirus; Protease Inhibitors; Reproducibility of Results; Simeprevir; Sofosbuvir; Spectrophotometry, Ultraviolet | 2019 |
Sofosbuvir-Based Therapies for Patients with Hepatitis C Virus Infection: Real-World Experience in China.
Topics: Adult; Antiviral Agents; Benzimidazoles; Carbamates; China; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Male; Middle Aged; Pyrrolidines; Retrospective Studies; RNA, Viral; Sofosbuvir; Sustained Virologic Response; Valine; Viral Nonstructural Proteins | 2018 |
Direct-acting antiviral therapy in sub-Saharan Africa.
Topics: Africa South of the Sahara; Antiviral Agents; Benzimidazoles; Fluorenes; Hepatitis C, Chronic; Humans; Rwanda; Sofosbuvir | 2019 |
Is there increased risk of hepatocellular carcinoma recurrence in liver transplant patients with direct-acting antiviral therapy?
Topics: Aged; Antiviral Agents; Benzimidazoles; Carcinoma, Hepatocellular; Disease-Free Survival; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Ribavirin; Simeprevir; Sofosbuvir; Sustained Virologic Response | 2019 |
Development and validation of a versatile HPLC-DAD method for simultaneous determination of the antiviral drugs daclatasvir, ledipasvir, sofosbuvir and ribavirin in presence of seven potential impurities. Application to assay of dosage forms and dissoluti
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Chromatography, High Pressure Liquid; Fluorenes; Imidazoles; Limit of Detection; Pyrrolidines; Reproducibility of Results; Ribavirin; Sensitivity and Specificity; Sofosbuvir; Solubility; Valine | 2019 |
Clinical, Virological Characteristics, and Outcomes of Treatment with Sofosbuvir/Ledipasvir in Two Pediatric Patients Infected by HCV Genotype 4.
Topics: Adolescent; Benzimidazoles; Child; Drug Resistance, Viral; Female; Fluorenes; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C; Humans; Phylogeny; Sofosbuvir; Treatment Outcome; Viral Nonstructural Proteins | 2019 |
Increased tenofovir monoester concentrations in patients receiving tenofovir disoproxil fumarate with ledipasvir/sofosbuvir.
Topics: Adenine; Adolescent; Adult; Antiviral Agents; Benzimidazoles; Blood Chemical Analysis; Chromatography, Liquid; Drug Interactions; Female; Fluorenes; Hepatitis C, Chronic; HIV Infections; Humans; Male; Middle Aged; Phosphorous Acids; Sofosbuvir; Tandem Mass Spectrometry; Tenofovir; Young Adult | 2019 |
Evolution of HCV patient characteristics and DAA regimens in the German Hepatitis C Registry (DHC-R) in 2014 and 2015.
Topics: Adult; Antiviral Agents; Benzimidazoles; Drug Combinations; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Prospective Studies; Registries; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2019 |
Higher relapse rate among HIV/HCV-coinfected patients receiving sofosbuvir/ledipasvir for 8 vs 12 weeks.
Topics: Antiviral Agents; Benzimidazoles; Coinfection; Female; Fluorenes; Hepatitis C, Chronic; HIV Infections; Humans; Male; Middle Aged; Recurrence; Retrospective Studies; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2019 |
Direct antiviral agents upregulate natural killer cell potential activity in chronic hepatitis C patients.
Topics: Adult; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepatitis C, Chronic; Humans; Immunity, Innate; Killer Cells, Natural; Longitudinal Studies; Male; Middle Aged; Natural Cytotoxicity Triggering Receptor 1; NK Cell Lectin-Like Receptor Subfamily C; Sofosbuvir; Time Factors; Young Adult | 2019 |
Effectiveness of 12 week ledipasvir/sofosbuvir and predictors of treatment failure in patients with hepatitis C.
Topics: Antiviral Agents; Benzimidazoles; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Liver Cirrhosis; Male; Middle Aged; Recurrence; Regression Analysis; Retrospective Studies; Sofosbuvir; Sustained Virologic Response; Treatment Failure | 2019 |
Real-world effectiveness and safety of ledipasvir/sofosbuvir for genotype 6 chronic hepatitis C patients in Taiwan.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepatitis C, Chronic; Humans; Male; Middle Aged; Safety; Sofosbuvir; Taiwan; Treatment Outcome | 2020 |
Flecainide plasma level modifications during ledipasvir/sofosbuvir coadministration in two patients affected by chronic hepatitis C.
Topics: Aged; Anti-Arrhythmia Agents; Antiviral Agents; Arrhythmias, Cardiac; Benzimidazoles; Drug Interactions; Drug Therapy, Combination; Flecainide; Fluorenes; Hepatitis C, Chronic; Humans; Male; Middle Aged; Sofosbuvir | 2019 |
Ledipasvir/Sofosbuvir versus Daclatasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Genotype 4 Patients.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Egypt; Female; Fluorenes; Genotype; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Random Allocation; Sofosbuvir; Treatment Outcome; Valine | 2020 |
Ribavirin induces hepatitis C virus genome mutations in chronic hepatitis patients who failed to respond to prior daclatasvir plus asunaprevir therapy.
Topics: Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Carbamates; Cell Line; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Genome, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Mutation; Pyrrolidines; Ribavirin; Sofosbuvir; Sulfonamides; Valine | 2020 |
Chemometrically Assisted Development of Ultra-High-Performance Liquid Chromatography Method for the Simultaneous Quantification of Sofosbuvir, Daclatasvir and Ledipasvir in Pharmaceutical Dosage Forms.
Topics: Benzimidazoles; Carbamates; Chromatography, High Pressure Liquid; Fluorenes; Imidazoles; Limit of Detection; Linear Models; Pyrrolidines; Reproducibility of Results; Sofosbuvir; Tablets; Valine | 2020 |
Resistance-associated substitution and ledipasvir/sofosbuvir therapy in Mongolian chronic hepatitis C patients.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepatitis C, Chronic; High-Throughput Nucleotide Sequencing; Humans; Male; Middle Aged; Mongolia; Sofosbuvir; Treatment Failure; Treatment Outcome; Uridine Monophosphate | 2020 |
[QOL Assessment in Chronic Hepatitis C Patients Receiving Ledipasvir/ Sofosbuvir or Simeprevir/Peginterferon/Ribavirin in Clinical Practice].
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Quality of Life; Recombinant Proteins; Ribavirin; Simeprevir; Sofosbuvir; Surveys and Questionnaires | 2019 |
High risk of hepatitis B virus reactivation among patients treated with direct-acting antivirals and coinfected with HCV and HIV.
Topics: Antiviral Agents; Benzimidazoles; Coinfection; Fluorenes; Hepatitis B virus; Hepatitis C, Chronic; HIV Infections; Humans; Recurrence; Sofosbuvir | 2020 |
Micellar-based spectrofluorimetric method for the selective determination of ledipasvir in the presence of sofosbuvir: application to dosage forms and human plasma.
Topics: Benzimidazoles; Drug Compounding; Fluorenes; Humans; Micelles; Molecular Structure; Sofosbuvir; Spectrometry, Fluorescence; Tablets | 2020 |
Hepatitis C virus therapy in children: No one should be left behind.
Topics: Benzimidazoles; Child; Child, Preschool; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Sofosbuvir | 2020 |
Hepatitis C Virus-associated Lymphoplasmacytic Lymphoma With Waldenström Macroglobulinemia: Response to Direct-acting Antiviral Therapy.
Topics: Benzimidazoles; Fluorenes; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Sofosbuvir; Waldenstrom Macroglobulinemia | 2020 |
A financial incentive program to improve appointment attendance at a safety-net hospital-based primary care hepatitis C treatment program.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Female; Fluorenes; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Middle Aged; Odds Ratio; Primary Health Care; Program Evaluation; Reward; Safety-net Providers; Sofosbuvir; Sustained Virologic Response; Young Adult | 2020 |
Ledipasvir/Sofosbuvir in Adolescents With Chronic Hepatitis C Genotype 4 With and Without Hematological Disorders: Virological Efficacy and Impact on Liver Stiffness.
Topics: Adolescent; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Elasticity Imaging Techniques; Female; Fluorenes; Hematologic Diseases; Hepacivirus; Hepatitis C, Chronic; Humans; Liver; Male; Sofosbuvir; Treatment Outcome | 2021 |
Effect of Hemodialysis on Efficacy and Pharmacokinetics of Sofosbuvir Coformulated with Either Daclatasvir or Ledipasvir in Patients with End-Stage Renal Disease.
Topics: Adult; Aged; Benzimidazoles; Carbamates; Clinical Trials as Topic; Drug Monitoring; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Imidazoles; Kidney Failure, Chronic; Male; Middle Aged; Pyrrolidines; Renal Dialysis; Sofosbuvir; Treatment Outcome; Valine | 2020 |
Real-world effectiveness of glecaprevir/pibrentasvir and ledipasvir/sofosbuvir for mixed genotype hepatitis C infection: A multicenter pooled analysis in Taiwan.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Cyclopropanes; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Taiwan | 2020 |
Development of a long-acting direct-acting antiviral system for hepatitis C virus treatment in swine.
Topics: Animals; Antiviral Agents; Benzimidazoles; Carbamates; Cost-Benefit Analysis; Disease Models, Animal; Drug Carriers; Drug Delivery Systems; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Imidazoles; Liver Cirrhosis; Models, Animal; Pyrrolidines; Ribavirin; Sofosbuvir; Swine; Valine | 2020 |
Sustained Virologic Suppression After 4 Weeks of Ledipasvir/Sofosbuvir in Human Immunodeficiency Virus (HIV)/Hepatitis C Virus (HCV) Co-Infection.
Topics: Adult; Antiviral Agents; Benzimidazoles; Coinfection; Drug Therapy, Combination; Fluorenes; Hepatitis C, Chronic; HIV Infections; Humans; Male; Sofosbuvir; Sustained Virologic Response | 2020 |
HCV eradication in chronic kidney disease: ready for prime time?
Topics: Benzimidazoles; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Renal Insufficiency, Chronic; Ribavirin; Sofosbuvir | 2020 |
Chronic Hepatitis C Virus Infection After Kidney Transplantation With or Without Direct-Acting Antivirals in a Real-Life Setting: A French Multicenter Experience.
Topics: Adult; Antiviral Agents; Benzimidazoles; Carbamates; Female; Fluorenes; France; Hepatitis C, Chronic; Humans; Imidazoles; Kidney Transplantation; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2020 |
Acute Renal Failure in a Patient on Ledipasvir-Sofosbuvir Therapy for Hepatitis C.
Topics: Acute Kidney Injury; Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Sofosbuvir; Treatment Outcome | 2020 |
Pharmacokinetics and renal safety of tenofovir alafenamide with boosted protease inhibitors and ledipasvir/sofosbuvir.
Topics: Adenine; Alanine; Anti-HIV Agents; Benzimidazoles; Fluorenes; HIV Infections; Humans; Protease Inhibitors; Sofosbuvir; Tenofovir | 2020 |
Real-world safety and effectiveness of ledipasvir/sofosbuvir for the treatment of chronic hepatitis C virus genotype 1 in Japan.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carcinoma, Hepatocellular; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Japan; Liver Neoplasms; Sofosbuvir; Sustained Virologic Response | 2021 |
Effectiveness and safety of ledipasvir/sofosbuvir for genotype 2 chronic hepatitis C infection: Real-world experience from Taiwan.
Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Taiwan; Treatment Outcome | 2021 |
Treatment of chronic hepatitis C virus infection with crushed ledipasvir/sofosbuvir administered through a percutaneous endoscopic gastrostomy tube in a patient with HIV coinfection.
Topics: Antiviral Agents; Benzimidazoles; Coinfection; Drug Therapy, Combination; Fluorenes; Gastrostomy; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Sofosbuvir; Treatment Outcome | 2021 |
Validated Reversed-Phase Liquid Chromatographic Method with Gradient Elution for Simultaneous Determination of the Antiviral Agents: Sofosbuvir, Ledipasvir, Daclatasvir, and Simeprevir in Their Dosage Forms.
Topics: Antiviral Agents; Benzimidazoles; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Fluorenes; Hepatitis C, Chronic; Limit of Detection; Simeprevir; Sofosbuvir; Temperature | 2020 |
Successful use of generic direct acting antiviral medications to treat hepatitis C-a New Zealand-wide study.
Topics: Aged; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Drugs, Generic; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; HIV Seropositivity; Humans; Imidazoles; Liver Cirrhosis; Male; Middle Aged; New Zealand; Pyrrolidines; Retrospective Studies; Sofosbuvir; Sustained Virologic Response; Valine; Viral Load | 2020 |
Efficacy and safety of ledipasvir/sofosbuvir in 5,028 Mongolian patients infected with genotype 1 hepatitis C virus: A multicenter study.
Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Mongolia; Sofosbuvir; Treatment Outcome | 2021 |
Outcomes of Hepatitis C Virus Treatment with Ledipasvir/Sofosbuvir in Mongolian Population: Successes and Challenges Facing Scale-up of Care.
Topics: Benzimidazoles; Fluorenes; Genotype; Hepacivirus; Humans; Sofosbuvir | 2021 |
Rapid and sensitive UHPLC-DAD method for simultaneous determination of sofosbuvir and ledipasvir in human serum.
Topics: Antiviral Agents; Benzimidazoles; Chromatography, High Pressure Liquid; Fluorenes; Hepatitis C, Chronic; Humans; Reproducibility of Results; Sofosbuvir | 2021 |
Sofosbuvir/Ledipasvir for Treatment of Chronic Hepatitis C Infection in Adult Patients with β- Thalassemia Major: A Real-Life Study.
Topics: Adult; Antiviral Agents; Benzimidazoles; beta-Thalassemia; Drug Therapy, Combination; Fluorenes; Genotype; Hepatitis C, Chronic; Humans; Retrospective Studies; Sofosbuvir; Thalassemia; Treatment Outcome; Uridine Monophosphate | 2022 |
Improvement in Liver Stiffness in Pediatric Patients with Hepatitis C Virus after Treatment with Direct Acting Antivirals.
Topics: Adolescent; Antiviral Agents; Aspartate Aminotransferases; Benzimidazoles; Child; Elasticity Imaging Techniques; Female; Fluorenes; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Prospective Studies; Sofosbuvir | 2021 |
Improvement of Skeletal Muscle Mass after Ledipasvir and Sofosbuvir Treatment for Hepatitis C Virus in Decompensated Liver Cirrhosis.
Topics: Aged; Antiviral Agents; Benzimidazoles; Female; Fluorenes; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Muscle, Skeletal; Quality of Life; Sofosbuvir; Treatment Outcome | 2021 |
Real-World Outcomes of Direct-Acting Antiviral Treatment and Retreatment in United Kingdom-Based Patients Infected With Hepatitis C Virus Genotypes/Subtypes Endemic in Africa.
Topics: Antiviral Agents; Benzimidazoles; Drug Combinations; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Retreatment; Sofosbuvir; Sustained Virologic Response | 2022 |
Ledipasvir/Sofosbuvir Eradicates Hepatitis C in an Immunodeficient STAT3-GOF Patient.
Topics: Antiviral Agents; Benzimidazoles; Child; Female; Fluorenes; Gain of Function Mutation; Genotype; Hepatitis C; Humans; Sofosbuvir; STAT3 Transcription Factor | 2021 |
Treatment of viral hepatitis C genotypes 1 and 2 by sofosbuvir and ledipasvir with or without ribavirin combination: A possible alternative to pangenotypic treatment in a low-income country?
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Developing Countries; Drug Interactions; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Male; Middle Aged; Retrospective Studies; Sofosbuvir; Treatment Outcome; Young Adult | 2021 |
Resistance-associated substitutions and response to treatment in a chronic hepatitis C virus infected-patient: an unusual virological response case report.
Topics: Antiviral Agents; Benzimidazoles; Drug Resistance, Viral; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; High-Throughput Nucleotide Sequencing; Humans; Male; Middle Aged; Recurrence; Ribavirin; RNA, Viral; Sofosbuvir; Sustained Virologic Response | 2021 |
Real-World Data from Turkey: Is Sofosbuvir/Ledipasvir With or Without Ribavirin Treatment for Chronic Hepatitis C Really Effective?
Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Ribavirin; Sofosbuvir; Treatment Outcome; Turkey | 2021 |
Beta-thalassemia major alters sofosbuvir/ledipasvir exposure in Hepatitis C virus infected adolescent patients.
Topics: Adolescent; Adult; Antiviral Agents; Benzimidazoles; beta-Thalassemia; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Pharmaceutical Preparations; Prospective Studies; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2021 |
Ledipasvir/Sofosbuvir for 8, 12, or 24 Weeks in Hepatitis C Patients Undergoing Dialysis for End-Stage Renal Disease.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Drug Administration Schedule; Female; Fluorenes; Hepatitis C; Humans; Kidney Failure, Chronic; Male; Middle Aged; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2021 |
Safety and efficacy of sofosbuvir/ledipasvir and sofosbuvir/daclatasvir in the treatment of hepatitis C in patients with decompensated cirrhosis.
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; End Stage Liver Disease; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Liver Cirrhosis; Pyrrolidines; Retrospective Studies; Severity of Illness Index; Sofosbuvir; Sustained Virologic Response; Treatment Outcome; Valine | 2021 |
Factors associated with a reduction in the quality of life of patients with chronic hepatitis C treated by ledipasvir/sofosbuvir therapy.
Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Quality of Life; Sofosbuvir | 2021 |
Innovative derivative/zero ratio spectrophotometric method for simultaneous determination of sofosbuvir and ledipasvir: Application to average content and uniformity of dosage units.
Topics: Benzimidazoles; COVID-19; Fluorenes; Humans; Reproducibility of Results; SARS-CoV-2; Sofosbuvir; Spectrophotometry | 2022 |
Ledipasvir/Sofosbuvir for Patients Coinfected With Chronic Hepatitis C and Hepatitis B in Taiwan: Follow-up at 108 Weeks Posttreatment.
Topics: Antiviral Agents; Benzimidazoles; Coinfection; DNA, Viral; Fluorenes; Follow-Up Studies; Hepacivirus; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis C; Hepatitis C, Chronic; Humans; Sofosbuvir; Taiwan | 2022 |
Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4-6 infection: Real-world evidence from a nationwide registry in Taiwan.
Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Middle Aged; Registries; Ribavirin; Sofosbuvir; Taiwan; Uridine Monophosphate | 2022 |
Assessment of outcome for sample of Iraqi patients with chronic hepatitis C virus infection treated by Ledipasvir/sofosbuvir drug.
Topics: Antiviral Agents; Benzimidazoles; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Pharmaceutical Preparations; Prospective Studies; Ribavirin; Sofosbuvir; Treatment Outcome; Uridine Monophosphate | 2021 |
The Influence of Treatment with Ledipasvir/Sofosbuvir on Growth Parameters in Children and Adolescents with Chronic Hepatitis C.
Topics: Adolescent; Antiviral Agents; Benzimidazoles; Child; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Male; Sofosbuvir; Treatment Outcome | 2022 |
Real-Life Data on Sofosbuvir/Ledipasvir in Patients with Chronic Viral Hepatitis C Genotype 1b: A Single-Center Experience.
Topics: Antiviral Agents; Benzimidazoles; Carcinoma, Hepatocellular; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Neoplasms; Sofosbuvir; Sustained Virologic Response; Treatment Outcome | 2022 |
Real-life experience of ledipasvir and sofosbuvir for HCV infected Korean patients: a multicenter cohort study.
Topics: Antiviral Agents; Cohort Studies; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Republic of Korea; RNA; Sofosbuvir; Treatment Outcome | 2022 |
In-depth investigation of the Silymarin effect on the pharmacokinetic parameters of sofosbuvir, GS-331007 and ledipasvir in rat plasma using LC-MS.
Topics: Animals; Antiviral Agents; Benzimidazoles; Chromatography, Liquid; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C; Male; Rats; Silymarin; Sofosbuvir; Tandem Mass Spectrometry | 2022 |
Safety and Efficacy of Ledipasvir/Sofosbuvir in the Treatment of Chronic Hepatitis C Virus Infection in Treatment-Naïve Children without and with Comorbidities.
Topics: Antiviral Agents; Benzimidazoles; Child; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Quality of Life; Sofosbuvir; Treatment Outcome | 2022 |
Ledipasvir/Sofosbuvir Is Effective for Relapsed Genotype 1b Hepatitis C Virus Patients after Achieving a Sustained Virological Response at Post-treatment Week 12 with Glecaprevir/Pibrentasvir.
Topics: Antiviral Agents; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Neoplasm Recurrence, Local; Ribavirin; Sofosbuvir | 2023 |
Impact of list price changes on out-of-pocket costs and adherence in four high-rebate specialty drugs.
Topics: Drug Costs; Health Expenditures; Hepatitis C; Humans; Medication Adherence; Retrospective Studies; Sofosbuvir | 2023 |
Ledipasvir/Sofosbuvir Is Effective as Sole Treatment of Porphyria Cutanea Tarda with Chronic Hepatitis C.
Topics: Antiviral Agents; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Porphyria Cutanea Tarda; Porphyrins; RNA; Sofosbuvir; Treatment Outcome | 2023 |
Non-ANCA Leucocytoclasic Vasculitis Induced by Sofosbuvir/Ledipasvir Treatment: A Case Report.
Topics: Antibodies, Antineutrophil Cytoplasmic; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Middle Aged; Sofosbuvir; Treatment Outcome; Vasculitis | 2024 |
Human pegivirus viremia in HCV/HIV co-infected patients: Direct acting antivirals exert anti-pegivirus effects.
Topics: Antiviral Agents; Coinfection; Female; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Interferons; Male; Pegivirus; Polyethylene Glycols; RNA, Viral; Sofosbuvir; Viremia | 2023 |